Burrows Raquel (Orcid ID: 0000-0001-9155-0689)
Villamor Eduardo (Orcid ID: 0000-0003-3937-5574)

Serum polyunsaturated fatty acids in infancy are associated with body composition in adolescence

Kerry Flannagan[1], Sheila Gahagan[2], Arun Das[3],

Raquel Burrows[4], Betsy Lozoff[5], and Eduardo Villamor[1]

[1]Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; [2]Division of Child Development and Community Health, University of California, San Diego, CA, USA; [3]Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; [4]Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile; [5]Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI, USA.

Keywords: polyunsaturated fatty acids; body composition; body mass index; children; infants; Chile

Running title: Polyunsaturated fatty acids and body composition

Author Manuscript

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ijpo.12656

This article is protected by copyright. All rights reserved.

Address correspondence to: E Villamor, Department of Epidemiology, University of Michigan School of Public Health, 1420 Washington Heights, SPH II, Room M5507, Ann Arbor, MI 48109; Tel: 734-615-2198; Fax: 734-764-3192; Email: villamor@umich.edu.

Abbreviations: PUFA, polyunsaturated fatty acids; IDA, iron deficiency anemia; FA, fatty acids; INTA, University of Chile Institute of Nutrition and Food Technology; DXA, dual energy X-ray absorptiometry; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; AA, arachidonic acid; D6D, Δ6-desaturase; D5D, Δ5-desaturase; BMI, body mass index; ToFM, total fat mass; TrFM, truncal fat mass; TLM, total lean mass; %ToFM, percent total fat mass; %TrFM, percent truncal fat mass; SES, socioeconomic status; CI, confidence interval; BMIZ, BMI-for-age Z score

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

ABSTRACT

Background: Polyunsaturated fatty acids (PUFA) have been related to the development of adiposity. N-3 PUFA appear to be protective against obesity risk, while n-6 PUFA may be associated with greater adiposity. However, most studies have been conducted among adults. The role of PUFA in infancy is unknown.

Objective: To examine associations of serum PUFA at age 1 y with age- and sex-adjusted body mass index Z score (BMIZ) change through age 16 y and body composition at 16 y.

Methods: We quantified serum PUFA in 636 Chilean infants aged 1 y. We measured BMIZ at ages 1, 5, 10, and 16 y, and body composition by dual energy X-ray absorptiometry at 16 y. We estimated differences in 1- to 16-y BMIZ change between PUFA quartiles from multivariable linear mixed models with restricted cubic splines. At 16 y, we estimated differences in total fat mass (ToFM), truncal fat mass (TrFM), total lean mass (TLM), percent total fat mass (%ToFM), and percent truncal fat mass (%TrFM) between PUFA quartiles using linear regression.

Results: PUFA were not associated with BMIZ change. Alpha-linolenic acid (ALA) was positively associated with TrFM (P=0.03) and %TrFM (P<0.0001) at 16 y while eicosapentaenoic acid (EPA) was inversely associated with %TrFM (P=0.001). Docosapentaenoic acid (DPA) was positively associated with ToFM (P=0.01), TrFM (P=0.009), %ToFM (P=0.02), and %TrFM (P=0.02). Gamma-linolenic acid (GLA) and the Δ6-desaturase (D6D) activity index were each positively, linearly associated with ToFM, TrFM,

This article is protected by copyright. All rights reserved.

and %ToFM. The Δ5-desaturase (D5D) activity index was inversely associated with %TrFM (P=0.04).

Conclusions: ALA, DPA, GLA, and the D6D index at 1 y of age were positively associated with adiposity at age 16 y, while EPA and the D5D index were inversely associated with central adiposity. Our results related to EPA and desaturase indices are in agreement with limited prior studies.

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

INTRODUCTION

Childhood obesity is the most prevalent early life risk factor for the development of chronic diseases, including type 2 diabetes, hypertension, and coronary heart disease.[1] Childhood obesity has increased globally throughout recent decades[2] and represents a significant public health concern. Identifying potentially modifiable nutritional exposures that influence the early development of adiposity is crucial in order to address this epidemic.

Polyunsaturated fatty acids (PUFA) are nutrients that may be related to the etiology of obesity. These fatty acids (FA), primarily classified into the n-3 and n-6 families, are necessary for a variety of physiologic processes. In particular, long-chain PUFA are precursors for eicosanoids, signaling molecules that regulate cardiovascular and immune function. In animal and *in vitro* studies, both plant- and marine-derived n-3 PUFA reduce or prevent adiposity, through reduction of fat deposition in adipose tissue and appetite suppression.[3,4] Conversely, n-6 PUFA upregulate adipocyte size and number.[5] Studies of PUFA and adiposity among adult humans have yielded mixed results. Some, but not all, trials of n-3 PUFA supplementation have found an inverse effect on adiposity.[6] While several observational studies (reviewed by Naughton et al[7]) report a positive association between the n-6 PUFA linoleic acid (18:2 n-6; LA) and body weight, a meta-analysis of n-6 PUFA supplementation trials did not find strong evidence for an effect of these PUFA on adiposity.[8]

PUFA status in infancy may be particularly influential on future adiposity. The precursor PUFA alpha-linolenic acid (18:3 n-3; ALA) and LA cannot be synthesized endogenously, and

This article is protected by copyright. All rights reserved.

their conversion into long-chain PUFA is inefficient in humans.[9] Thus infants must largely obtain these FA through diet, initially from breast milk or formula[10] and later through complementary feeding. Nutrition during infancy can have long-term effects on cardiovascular health.[11] Adipose tissue in childhood may be especially sensitive to the effects of PUFA, since this is the time during which the number of adipocytes in the body is determined.[12] Most previous investigations of early-life PUFA and adiposity have focused on exposure *in utero*.[13] The potential effects of PUFA in infancy may differ from those *in utero,* but results from previous studies have been inconclusive, and little research exists on measures of long-term adiposity. In a recent review of both observational studies and trials of n-3 PUFA supplementation in infancy, results were a mix of positive, inverse, and null associations of specific PUFA with measures of adiposity through middle childhood.[13] In addition to these inconclusive findings, the outcomes in these studies were assessed at ages 6-8 y, and thus it is still unclear whether PUFA might have longer-reaching effects on adiposity throughout development. Moreover, very few studies have been conducted in low- and middle-income countries,[14-16] despite the rapidly growing burden of childhood obesity[2] and low availability of dietary PUFA[17] affecting many of these regions.

We aimed to investigate the relations between serum PUFA biomarkers at 1 y of age and measures of adiposity at age 16 y in a cohort of children from Santiago, Chile.

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

METHODS

Study design and population. We conducted a longitudinal investigation among Chilean children who were enrolled as infants in studies on iron status and were followed through adolescence. Details of the study design have been published previously.[18,19] Briefly, participants were recruited at ages 4-6-months from low- and middle-income communities in Santiago, Chile between 1991 and 1996. Eligible infants were singleton, born at term weighing at least 3 kg through uncomplicated, vaginal births, and did not have major health complications. Infants without iron deficiency anemia (IDA) at baseline were enrolled in a trial of iron supplementation. These participants were randomly assigned to high- or low-dose iron supplementation or usual nutrition until 12 months of age. Infants with IDA were treated with iron and enrolled in an observational study of neurodevelopment, along with a group of non-anemic controls. There were 1798 infants enrolled; of these, 1657 completed the trial and 135 were in the neurodevelopment study at 6 months. The cohort was followed during middle childhood and adolescence: 888 children were assessed at 5 y of age, 1127 at 10 y of age, and a subset of 679 were assessed at a mean age of 16.8 y of age as part of a study on cardiometabolic risk.[20] The study of FA was conducted among participants who had a stored serum sample available from age 1 y plus at least one more sample from ages 5 or 10 y. For analyses of BMIZ change between 1 and 16 y of age, we included 636 children in the FA study who had BMIZ data available at 1 y of age and at $\geq$ 1 subsequent assessment (5, 10, or 16 y of age). For the analysis of PUFA at 1 y of age and DXA measures of body composition at 16 y of age, there were 382

This article is protected by copyright. All rights reserved.

children with available information. A flowchart of the sample size at each inclusion step is provided in **Figure S1**.

The study procedures were approved by institutional review boards at the University of Chile Institute of Nutrition and Food Technology (INTA), the University of Michigan, and the University of California, San Diego. Parents provided written informed consent to participate for their children, and children provided written assent beginning at 10 y of age.

Data collection. Birth weight in g, length in cm, and gestational age in weeks were determined via hospital records. The date of the mother's last menstrual period was used to determine gestational age. Study personnel collected information from parents on household socioeconomic indicators at enrollment. Information on breastfeeding habits, including the date of the first bottle feeding and last breastfeeding, were collected from mothers at weekly study visits that took place from enrollment until the infant was 12 months old. For infants who had already been bottle fed at enrollment, mothers were asked to recall the date of the first bottle feeding. Because feeding breast milk by bottle was nonexistent in this population, bottle feeding was equivalent to giving infant formula or cow milk.

Anthropometric measurements were collected at INTA by trained study personnel using standardized techniques. At 1 y of age, weight was measured unclothed to the nearest 10 g and length was measured to the nearest millimeter using a recumbent length board. Weight at 5, 10 and 16 y was measured to the nearest 100 g using a Seca scale (Seca, Hamburg, Germany) and height was measured to the nearest millimeter using a Holtain stadiometer (Holtain, Crymych,

Author Manuscript

This article is protected by copyright. All rights reserved.

UK). All measures were obtained in duplicate and a third measurement was taken if the difference between the first two was greater than 0.3 kg or 0.5 cm; the mean of the two closest values was used. At the 16.8 y assessment, total fat mass, truncal fat mass, and total lean mass were measured with a dual energy X-ray absorptiometry (DXA) instrument (Lunar Prodigy Corp., Madison, WI, USA). These measures were conducted in the subset of children who participated in the study of cardiometabolic risk.

A blood sample was collected by venipuncture at 1, 5 and 10 y of age. The median (25^{th}, 75^{th} percentile) age at the 1 y blood draw was 1.00 y (0.99, 1.02). Blood components were separated and serum samples from 1 y of age were stored at -80˚C before transportation as a single batch to the University of Michigan where they were cryostored at -80˚C and analyzed after approximately 20 y from collection. Serum PUFA stored at -80˚C are highly stable. A previous study found virtually no degradation of PUFA in samples stored at -80˚C for up to 10 years.[21]

Fatty acid analyses. FA in serum were quantified at the University of Michigan Regional Comprehensive Metabolomics Resource Core. Total lipids were extracted from 200 µl of serum according to the method described by Bligh and Dyer.[22] 10 µL of 4 mM nonadecanoic acid (C19:0) was used as the internal standard. The FA fraction of the total lipids was derivatized into methyl esters using BF_3-methanol as previously described.[23] These were extracted with a 2:1 hexane-water, dried, and resuspended in hexane. FA were measured using gas chromatography. 1-2 µL of sample was injected via autosampler onto an Agilent 6890N chromatograph (Agilent,

This article is protected by copyright. All rights reserved.

Author Manuscript

Santa Clara, CA, USA) with a flame ionization detector, a 100 m x 0.25 mm x 0.2 μm SP-2560 column (Sigma-Aldrich, Bellefonte, PA, USA) and Chemstation software. C19:0 and other authentic methyl esters were used to create a calibration curve for FA quantification. The authentic methyl esters were also used to identify FA in samples based on retention times. The coefficients of variation for quantification of specific FA ranged between 2.5-3.6%.

Statistical Analyses. *Definition of exposures*. The main exposures were serum PUFA biomarkers measured at 1 y of age, expressed as percentage relative to the total FA concentration (FA %) quantified in a sample. The n-3 PUFA we considered were ALA, eicosapentaenoic acid (20:5 n-3; EPA), docosapentaenoic acid (22:5 n-3; DPA), and docosahexaenoic acid (22:6 n-3; DHA). N-6 PUFA included LA, gamma-linolenic acid (18:3 n-6; GLA), dihomo-gamma-linolenic acid (20:3 n-6; DGLA), and arachidonic acid (20:4 n-6; AA). We also considered the ratio of total n-6:n-3 PUFA, which may be important for adiposity development.[24] Additionally, we considered activity indices of the Δ6-desaturase (D6D) and Δ5-desaturase (D5D) enzymes, using the GLA/LA and AA/DGLA ratios, respectively. We categorized all exposures into quartiles to allow for possible non-linear associations with the outcomes.

Definition of outcomes. The primary outcomes were change in age- and sex-adjusted body mass index (BMI) Z scores (BMIZ) between 1 and 16 y of age and DXA measures of body composition at 16 y of age. BMI was calculated as kg/m^2 and BMIZ were calculated according to the World Health Organization Growth Reference for children ages 5-19 y.[25] DXA measures

Author Manuscript

This article is protected by copyright. All rights reserved.

included the total fat mass (ToFM), truncal fat mass (TrFM), total lean mass (TLM), percent total fat mass (%ToFM), and percent truncal fat mass (%TrFM).

Covariates. All covariates were measured in infancy and included sociodemographic and anthropometric characteristics as well as serum FA. We categorized birth length and weight as average or large for gestational age according to the INTERGROWTH 21st standards for newborn size.[26] We defined large for gestational age as ≥90th percentile. We did not consider a category of small for gestational age because birth weight ≥3 kg was an eligibility criterion for recruitment and there were no children ≤10th percentile for birth weight. Seven children with birth length ≤10th percentile were classified in the average for gestational age group. We categorized breastfeeding as <6 months, ≥6 months mixed bottle/breastfeeding, or ≥6 months exclusive breastfeeding. Iron supplementation was categorized as any (combining low- and high-dose groups) vs. none. We measured socioeconomic status (SES) using a modified Graffar index.[27] The index consists of 13 items related to family structure, education and employment, crowding and housing condition, and ownership of assets. The index ranges from 0 to 65; higher values indicate lower SES. The serum FA that we considered as covariates were total *trans* FA, which have been associated with weight gain in adults.[28]

Correlates of serum PUFA at 1 y of age. We compared distributions of serum PUFA biomarkers by categories of covariates using means ± SD. We tested the significance of associations using linear regression models with each PUFA biomarker as the outcome. For dichotomous covariates, we obtained P values from Wald tests. For ordinal variables, we tested

Author Manuscript

This article is protected by copyright. All rights reserved.

for linear trends using Wald tests of a variable representing category-specific medians introduced as a continuous variable. For categorical covariates, we used a χ^2 score statistic. We specified robust estimates of variance in all models.

Serum PUFA at 1 y of age and change in BMIZ from ages 1 to 16 y. In bivariate analysis, we estimated means ± SE of BMIZ at 1 and 16 y of age and change in BMIZ between 1 and 16 y by quartiles of the PUFA exposures at age 1 y. These were from BMIZ growth curves estimated using mixed effects linear regression models.[29] The outcome was BMIZ and age was represented as a predictor using restricted cubic splines.[30] These piecewise cubic polynomials are smoothly joined at each knot and linear in the tails. They allow for modeling of smoothed, non-linear trajectories of BMIZ across different ages. These methods do not require that all children have the same number of measurements or that the measurements be obtained at the same ages. Thus, we fitted the models with data from all assessments (1, 5, 10, and 16 y) and placed knots at the median ages of children measured at each assessment. Other predictors in the model included indicator variables for each PUFA quartile, interaction terms between the PUFA indicators and all age terms, and random intercepts and age slopes for each child. We estimated adjusted mean differences and 95% confidence intervals (CI) in 1 to 16 y BMIZ change between quartiles of serum PUFA from these models. We included covariates that were associated with the PUFA biomarkers or that have been related to BMIZ change. The final model included sex, birth weight, breastfeeding, Graffar index, and total serum *trans* FA at 1 y of age. Each long-chain PUFA was adjusted for its immediate metabolic precursor: EPA was adjusted for ALA, DPA for

Author Manuscript

This article is protected by copyright. All rights reserved.

EPA, DHA for DPA, GLA for LA, DGLA for GLA, and AA for DGLA. In order to adjust for potential confounding by common dietary sources of n-3 and n-6 PUFA, which co-occur as LA and ALA in foods such as plant oils,[31] we adjusted estimates for each n-3 PUFA for LA and total long-chain n-6 PUFA, while estimates for each n-6 PUFA were adjusted for ALA and total long-chain n-3 PUFA. All covariate FA were entered in the model as restricted cubic splines in order to account for possible residual confounding due to non-linear associations with the outcome. When the association between PUFA quartiles and BMIZ change seemed linear, we estimated the difference in change per 1 SD of the PUFA distribution.

Serum PUFA at 1 y of age and body composition at 16 y. In bivariate analysis, we compared distributions of ToFM, TrFM, TLM, %ToFM, and %TrFM by quartiles of serum PUFA using means ± SD. We conducted tests for linear trend using linear regression models with each body composition measure as the outcome and a variable representing median values of each PUFA quartile introduced as a continuous variable. In multivariable analysis we obtained adjusted mean differences and 95% CI in the body composition measures by quartiles of serum PUFA. These models included indicators for PUFA quartiles and were also adjusted for sex, birth weight, breastfeeding, Graffar index, BMI at 1 y of age, and total serum *trans* FA. We also included other PUFA as covariates following the strategy described for the analyses of BMIZ change. Because body composition may differ by sex in adolescence, we conducted supplemental analyses stratified by sex by including interaction terms between sex and all other model predictors and testing for their statistical significance.

Author Manuscript

This article is protected by copyright. All rights reserved.

We fitted all models with empirical variance estimates, which are robust to heteroskedasticity and deviations from normality.[32] All analyses were conducted using Statistical Analysis Software version 9.4 (SAS Institute, Cary, NC, USA).

Author Manuscript

This article is protected by copyright. All rights reserved.

RESULTS

The number of children with 2, 3, or 4 measurements was 78, 183, and 375, respectively. Mean ± SD BMIZ at 1, 5, 10, and 16 y of age was 0.81 ± 0.94, 0.98 ± 1.18, 1.02 ± 1.16, and 0.71 ± 1.13, respectively. At age 16 y, mean ± SD ToFM, TrFM, and LM was 19.8 ± 10.1, 10.0 ± 5.7, and 44.0 ± 8.9 kg, respectively. Mean ± SD %ToFM and %TrFM was 29.1 ± 10.9 and 49.3 ± 5.9.

N-3 PUFA

Correlates of n-3 PUFA at 1 y. Serum ALA was positively associated with iron supplementation (**Table S1**). EPA was positively related to exclusive breastfeeding duration and total *trans* FA. DPA was inversely associated with iron supplementation. DHA was related to female sex and exclusive breastfeeding duration, and inversely associated with total serum *trans* FA.

BMIZ change between ages 1 and 16 y. N-3 PUFA at 1 y of age were not significantly associated with BMIZ change from 1 to 16 y (**Table 1 and Table S2**).

Body composition at age 16 y. ALA was positively associated with TrFM and %TrFM in non-linear fashions (**Table 2 and Table S2**). Adjusted mean differences (95% CI) between children with ALA in quartile (Q) 4 vs. <Q4 were 1.5 kg (0.2, 2.8; P=0.03) for TrFM and 3.3 percentage points (95% CI: 2.0%, 4.6%; P<0.0001) for %TrFM. EPA was inversely associated with %TrFM (adjusted mean difference >Q1 vs. Q1: -2.1%; 95% CI: -3.5%, -0.9%; P=0.001). DPA was positively associated with fat mass indices in non-linear manners. Adjusted mean

Author Manuscript

This article is protected by copyright. All rights reserved.

differences (95% CI) between DPA >Q1 vs. Q1 for ToFM, TrFM, %ToFM, and %TrFM were, respectively, 2.7 kg (95% CI: 0.7, 4.8; *P*=0.01), 1.6 kg (95% CI: 0.4, 2.8; *P*=0.009), 2.3% (95% CI: 0.4, 4.2; *P*=0.02), and 1.8% (95% CI: 0.3, 3.2; *P*=0.02). Most associations did not differ by sex (**Table S3 and Table S4**). However, the positive association of ALA with %TrFM was stronger among boys (*P*, interaction=0.02), as was the inverse association of EPA with %TrFM (*P*, interaction=0.004).

N-6 PUFA

Correlates of n-6 PUFA at 1 y. LA was positively associated with exclusive breastfeeding ≥6 months and with iron supplementation (**Table S5**). It was inversely associated with total *trans* FA. Serum GLA was inversely related to length-for-gestational age and socioeconomic status. DGLA was positively associated with length- and weight-for-gestational age and inversely related to iron supplementation. AA was positively associated with length- and weight-for-gestational age, and exclusive breastfeeding ≥6 months, and inversely related to iron supplementation and total *trans* FA. The n-6:n-3 ratio was inversely associated with total *trans* FA. The D6D index was inversely associated with length-for-gestational age and socioeconomic status.

BMIZ change between ages 1 and 16 y. Neither n-6 PUFA, the n-6:n-3 ratio, nor desaturase indices at 1 y of age was significantly associated with change in BMIZ (**Table 3 and Table S6**).

Author Manuscript

This article is protected by copyright. All rights reserved.

Body composition at 16 y of age. Without adjustment for n-3 PUFA, GLA (*P*, trend=0.02) and the D6D index (*P*, trend=0.01) were each positively associated with %ToFM (**Table S6**). In fully adjusted models, GLA and the D6D index were each positively, linearly associated with ToFM, TrFM, and %ToFM (**Table 4**). Every 1 SD (0.36) difference in GLA was associated with an adjusted higher mean ToFM (1.0 kg per SD; 95% CI: 0.1, 1.9; *P*=0.03), TrFM (0.6 kg per SD; 95% CI: 0.1, 1.1; *P*=0.03), and %ToFM (1.0 percentage points per SD; 95% CI: 0.2%, 1.7%; *P*=0.01). A 1 SD difference (0.02) in the D6D index was related to a higher mean ToFM (1.2 kg per SD; 95% CI: 0.0, 2.3; *P*=0.04), TrFM (0.7 kg per SD; 95% CI: 0.0, 1.4; *P*=0.05), and %ToFM (1.1 percentage points per SD; 95% CI: 0.2%, 2.1%; *P*=0.02). The D5D index was inversely associated with %TrFM. Children in the highest quartile had a mean %TrFM 1.9 percentage points lower than did children in the lowest quartile (95% CI: -3.8%, -0.1%; *P*=0.04). A slight inverse association between DGLA and %TrFM was present only among girls (*P*, interaction=0.02); no other associations differed by sex (**Table S7 and Table S8**).

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

DISCUSSION

In this longitudinal study of Chilean children, PUFA at 1 y of age were not associated with BMIZ changes through childhood and adolescence. Nevertheless, they were related to body composition at age 16 y. Serum ALA at 1 y of age was positively associated with TrFM and %TrFM at 16 y. EPA was inversely associated with %TrFM, while DPA was positively associated with ToFM, TrFM, %ToFM, and %TrFM. GLA and the D6D index were each positively associated with ToFM, TrFM, and %ToFM. The D5D index was inversely associated with %TrFM.

Serum ALA was positively associated with truncal fat. This is in contrast to a previous study in which maternal plasma ALA during pregnancy was inversely associated with the android/gynoid fat mass ratio and pre-peritoneal fat mass area in offspring at 6 y of age.[33] One potential explanation for this discrepancy is the difference in ages at which body composition was measured in the two studies. Body composition may not track completely between childhood and adolescence. Thus, the relation between early-life ALA and body composition at 6 y of age may be different than its relation with body composition at 16 y. Other possible explanations include the differences in timing of exposure assessment, measures of central adiposity, or ALA intake between the study populations. Four other studies of early-life ALA exposure and measures of adiposity have used BMI as an outcome, which does not distinguish between fat compartments. None of these found associations between ALA in cord blood[34,35] or breastmilk[15,36] with BMI during infancy or childhood, consistent with our finding of no

This article is protected by copyright. All rights reserved.

association with BMI change. The mechanism underlying a potential effect of ALA on central adiposity is unclear. One possibility is that much of the serum ALA measured in these children could have been *trans* ALA. In areas where hydrogenated oils are present in the food supply, *trans* ALA represents a large proportion of total dietary ALA.[37] Chile had not banned *trans* FA from its food supply at the time of FA measurement in this study.[38] Although few studies have investigated the health effects of *trans* ALA, other *trans* FA have been positively associated with central adiposity.[39] We did not measure *trans* isomers of ALA and could not differentiate its effects from those of *cis* ALA. The association could also be due to confounding by unmeasured aspects of diet.

We found that EPA was inversely associated with %TrFM. In a randomized trial, supplementation with EPA+DHA from birth to 6 months resulted in lower waist circumference at 5 y of age.[40] In another study, maternal plasma EPA during pregnancy was inversely associated with the android/gynoid fat mass ratio and pre-peritoneal fat mass area at 6 y.[33] Previous studies of EPA during pregnancy, in cord blood, or in breastmilk have not consistently found protective associations with measures of overall adiposity such as BMI and %ToFM.[13] However, our results and others suggest that EPA may be specifically protective against central adiposity, which is related to development of the metabolic syndrome[41] and cardiovascular disease.[42] Whether early-life EPA decreases risk of future chronic disease remains to be investigated.

Author Manuscript

This article is protected by copyright. All rights reserved.

DPA at age 1 y was positively associated with ToFM, TrFM, %ToFM, and %TrFM at 16 y. In a pooled analysis of two large cohorts, cord blood DPA was not associated with childhood BMI.[43] Maternal DPA during pregnancy was inversely associated with %ToFM and the android/gynoid fat mass ratio at 6 y in a Dutch study.[33] Compared with EPA, DPA is found at lower levels in the diet[44] and may be less bioavailable.[45] Thus, DPA in serum could more closely reflect endogenous activity of D6D than it does DPA intake. Associations between DPA and fat mass might reflect associations with D6D activity rather than an effect of DPA itself.

GLA was positively associated with ToFM, TrFM, and %ToFM. This is in agreement with an investigation that reported a positive association between maternal plasma GLA during pregnancy and %ToFM and pre-peritoneal fat mass area in offspring at age 6 y.[33] However, two other studies found no association between cord blood GLA and BMI or %ToFM in childhood.[43,46] A trial of formula supplemented with GLA+DHA until 9 months of age found no effect on BMI or %ToFM at age 10 y.[47] Differences among studies may be the result of differences in GLA levels between populations, or effect modification by desaturase gene variations.[48]

Estimated D6D enzyme activity was positively associated with ToFM, TrFM, and %ToFM, while the D5D index was inversely associated with %TrFM. Our results are consistent with two longitudinal studies conducted among children aged 2-10 y[49] and 10 y,[50] and evidence that cardiometabolic risk factors are positively related to D6D activity and inversely associated with D5D activity among adults.[51]

Author Manuscript

This article is protected by copyright. All rights reserved.

Although PUFA in infancy were related to body composition in adolescence, they were not associated with BMIZ trajectories. These results are unexpected since BMI and BMIZ correlate with fat mass throughout childhood. One possible explanation is that the differences in body composition at 16 y by PUFA concentrations may already have been present at 1 y. We tried to overcome this possibility by adjusting the analyses of body composition measures at age 16 y for BMI at 1 y, but BMI in infancy is an imperfect proxy for fat mass. Another possibility is that the outcomes measured by DXA are more precise measures of adiposity than BMIZ, which reflects both fat and lean mass, or that the effects of PUFA differ between body fat compartments, which are not separated by using BMIZ.

One of the primary strengths of this study is its longitudinal design, which limits the possibility of reverse causation. We had an opportunity to examine associations of early-life exposures with outcomes at older ages, which provides evidence for the relevance of PUFA status in infancy for long-term health. PUFA biomarkers are not subject to errors in recall or food composition tables, as opposed to dietary assessment data. Furthermore, we assessed body composition using DXA, which provides reliable and valid measures of fat and lean mass.[52]

One of the limitations of this study is that serum PUFA biomarkers reflect status over a period of weeks and may misclassify participants with respect to long-term intake.[53] Analyses of multiple exposures could have increased type I error. Body composition measures differ by sex in adolescence[54]; although interactions by sex were not statistically significant, effect modification by sex cannot be completely ruled out. The lack of available body composition

Author Manuscript

This article is protected by copyright. All rights reserved.

measurements in infancy prevented us from analyzing change in these outcomes or adjusting for their baseline values. Adiposity at 1 y of age could have influenced serum PUFA levels at 1 y of age, and this reverse causation may have influenced the results related to BMIZ trajectories. However, we chose not to adjust for baseline BMIZ in these analyses because this adjustment can cause bias.[55] Measured baseline BMIZ is the result of both true baseline BMIZ and its measurement error, which in turn contributes to measured BMIZ change from baseline to 16 y, the outcome of interest. As a common effect of two variables (a "collider"), baseline BMIZ naturally blocks the flow of a non-causal statistical association between the exposure (PUFA) and the outcome. Adjusted for baseline BMIZ could unblock such a non-causal path and induce a spurious association between PUFA and BMIZ change from baseline to later ages. Finally, because we only had relative measures of serum PUFA expressed as a percentage of total FA, we were unable to determine the extent to which differences in PUFA FA percentage reflect differences in absolute serum PUFA content or serum levels of saturated, monounsaturated, and *trans* FA.

In conclusion, serum ALA and DPA at 1 y of age were positively associated with measures of fat mass at age 16 y, whereas EPA was inversely associated with %TrFM. GLA and the D6D index were also positively associated with adiposity in adolescence, while D5D activity was inversely related to this outcome. PUFA status in infancy might affect long-term body composition and adiposity. Our results could be generalizable to other populations with similar dietary intake and behavior, which in this Chilean population have been characterized as low in

Author Manuscript

This article is protected by copyright. All rights reserved.

fruits and vegetables, high in snack foods with saturated fat and refined carbohydrates, and low in physical activity levels.[56] Our results may also be applicable to populations undergoing a similar nutrition transition. In Chile, economic growth in the 1990s resulted in one of the most rapid transitions in Latin America, including a shift toward Western diets and sedentary lifestyles.[57] By the time of the 16 y follow-up in our study, the transition was advanced with a very low prevalence of stunting and high prevalence of obesity.[58] Intervention studies are warranted to elucidate the potential protective effect of EPA against the development of central adiposity in children and adolescents.

Author Manuscript

This article is protected by copyright. All rights reserved.

CONFLICT OF INTEREST STATEMENT

The authors report no conflicts of interest.

Author Manuscript

This article is protected by copyright. All rights reserved.

ACKNOWLEDGMENTS

EV, SG, and BL designed the research. SG, BL, and AD conducted the research. KF performed the data analysis. KF and EV wrote the paper and had primary responsibility for the final content. All authors read and approved the final manuscript.

The study was funded by grants HL117860, HD033487, and HL088530 from the National Institutes of Health. Fatty acids were quantified using Core Services supported by grant DK097153 from the National Institutes of Health to the University of Michigan.

Author Manuscript

This article is protected by copyright. All rights reserved.

REFERENCES

1. Park MH, Falconer C, Viner RM, Kinra S. The impact of childhood obesity on morbidity and mortality in adulthood: a systematic review. *Obes Rev.* 2012;13(11):985-1000.
2. (NCD-RisC) NRFC. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet.* 2017;390(10113):2627-2642.
3. Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. *Obes Rev.* 2009;10(6):648-659.
4. Leikin-Frenkel A, Shomonov-Wagner L, Juknat A, Pasmanik-Chor M. Maternal Diet Enriched with alpha-Linolenic or Saturated Fatty Acids Differentially Regulates Gene Expression in the Liver of Mouse Offspring. *J Nutrigenet Nutrigenomics.* 2015;8(4-6):185-194.
5. Muhlhausler BS, Ailhaud GP. Omega-6 polyunsaturated fatty acids and the early origins of obesity. *Curr Opin Endocrinol Diabetes Obes.* 2013;20(1):56-61.
6. Martinez-Victoria E, Yago MD. Omega 3 polyunsaturated fatty acids and body weight. *Br J Nutr.* 2012;107 Suppl 2:S107-116.
7. Naughton SS, Mathai ML, Hryciw DH, McAinch AJ. Linoleic acid and the pathogenesis of obesity. *Prostaglandins Other Lipid Mediat.* 2016;125:90-99.

Author Manuscript

This article is protected by copyright. All rights reserved.

8. Hooper L, Al-Khudairy L, Abdelhamid AS, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev.* 2018;11:Cd011094.

9. Shils ME, Shike M. *Modern Nutrition in Health and Disease.* Lippincott Williams & Wilkins; 2006.

10. Carlson SE, Colombo J. Docosahexaenoic Acid and Arachidonic Acid Nutrition in Early Development. *Adv Pediatr.* 2016;63(1):453-471.

11. Kinra S, Rameshwar Sarma KV, Ghafoorunissa, et al. Effect of integration of supplemental nutrition with public health programmes in pregnancy and early childhood on cardiovascular risk in rural Indian adolescents: long term follow-up of Hyderabad nutrition trial. *Bmj.* 2008;337:a605.

12. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. *Nature.* 2008;453(7196):783-787.

13. Voortman T, van den Hooven EH, Braun KV, et al. Effects of polyunsaturated fatty acid intake and status during pregnancy, lactation, and early childhood on cardiometabolic health: A systematic review. *Prog Lipid Res.* 2015;59:67-87.

14. Stein AD, Wang M, Martorell R, et al. Growth to age 18 months following prenatal supplementation with docosahexaenoic acid differs by maternal gravidity in Mexico. *J Nutr.* 2011;141(2):316-320.

Author Manuscript

This article is protected by copyright. All rights reserved.

15. Tinoco SM, Sichieri R, Setta CL, Moura AS, Carmo MG. n-3 polyunsaturated fatty acids in milk is associate to weight gain and growth in premature infants. *Lipids Health Dis.* 2009;8:23.

16. van der Merwe LF, Moore SE, Fulford AJ, et al. Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development. *Am J Clin Nutr.* 2013;97(1):45-57.

17. Petrova S, Dimitrov P, Willett WC, Campos H. The global availability of n-3 fatty acids. *Public Health Nutr.* 2011;14(7):1157-1164.

18. Lozoff B, De Andraca I, Castillo M, Smith JB, Walter T, Pino P. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. *Pediatrics.* 2003;112(4):846-854.

19. Roncagliolo M, Garrido M, Walter T, Peirano P, Lozoff B. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. *Am J Clin Nutr.* 1998;68(3):683-690.

20. Burrows R, Correa-Burrows P, Reyes M, Blanco E, Albala C, Gahagan S. High cardiometabolic risk in healthy Chilean adolescents: associations with anthropometric, biological and lifestyle factors. *Public Health Nutr.* 2016;19(3):486-493.

21. Matthan NR, Ip B, Resteghini N, Ausman LM, Lichtenstein AH. Long-term fatty acid stability in human serum cholesteryl ester, triglyceride, and phospholipid fractions. *J Lipid Res.* 2010;51(9):2826-2832.

Author Manuscript

This article is protected by copyright. All rights reserved.

22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol.* 1959;37(8):911-917.

23. Morrison WR, Smith LM. PREPARATION OF FATTY ACID METHYL ESTERS AND DIMETHYLACETALS FROM LIPIDS WITH BORON FLUORIDE--METHANOL. *J Lipid Res.* 1964;5:600-608.

24. Rudolph MC, Jackman MR, Presby DM, et al. Low Neonatal Plasma n-6/n-3 PUFA Ratios Regulate Offspring Adipogenic Potential and Condition Adult Obesity Resistance. *Diabetes.* 2018;67(4):651-661.

25. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. *Bull World Health Organ.* 2007;85(9):660-667.

26. Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet.* 2014;384(9946):857-868.

27. Alvarez ML, Muzzo S, Ivanovic D. [Scale for measurement of socioeconomic level, in the health area]. *Rev Med Chil.* 1985;113(3):243-249.

28. Thompson AK, Minihane AM, Williams CM. Trans fatty acids and weight gain. *Int J Obes (Lond).* 2011;35(3):315-324.

29. Perng W, Mora-Plazas M, Marin C, Villamor E. Iron status and linear growth: a prospective study in school-age children. *Eur J Clin Nutr.* 2013;67(6):646-651.

Author Manuscript

This article is protected by copyright. All rights reserved.

30. Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med.* 1989;8(5):551-561.

31. Baylin A, Mora-Plazas M, Cobos-de Rangel O, Lopez-Arana S, Campos H, Villamor E. Predictors of usage and fatty acid composition of cooking fats in Bogota, Colombia. *Public Health Nutr.* 2009;12(4):531-537.

32. White H. A Heteroskedasticity-Consistent Covariance-Matrix Estimator and a Direct Test for Heteroskedasticity. *Econometrica.* 1980;48(4):817-838.

33. Vidakovic AJ, Gishti O, Voortman T, et al. Maternal plasma PUFA concentrations during pregnancy and childhood adiposity: the Generation R Study. *Am J Clin Nutr.* 2016;103(4):1017-1025.

34. Donahue SM, Rifas-Shiman SL, Gold DR, Jouni ZE, Gillman MW, Oken E. Prenatal fatty acid status and child adiposity at age 3 y: results from a US pregnancy cohort. *Am J Clin Nutr.* 2011;93(4):780-788.

35. Helland IB, Smith L, Blomen B, Saarem K, Saugstad OD, Drevon CA. Effect of supplementing pregnant and lactating mothers with n-3 very-long-chain fatty acids on children's IQ and body mass index at 7 years of age. *Pediatrics.* 2008;122(2):e472-479.

36. Scholtens S, Wijga AH, Smit HA, et al. Long-chain polyunsaturated fatty acids in breast milk and early weight gain in breast-fed infants. *Br J Nutr.* 2009;101(1):116-121.

37. Wolff R. *trans*-Polyunsaturated fatty acids in French edible rapeseed and soybean oils. *Journal of the American Oil Chemists' Society.* 1992;69(2):106-110.

Author Manuscript

This article is protected by copyright. All rights reserved.

38. Colon-Ramos U, Monge-Rojas R, Campos H. Impact of WHO recommendations to eliminate industrial trans-fatty acids from the food supply in Latin America and the Caribbean. *Health Policy Plan.* 2014;29(5):529-541.

39. Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. *Nat Rev Endocrinol.* 2009;5(6):335-344.

40. See VHL, Mori TA, Prescott SL, Beilin LJ, Burrows S, Huang RC. Cardiometabolic Risk Factors at 5 Years After Omega-3 Fatty Acid Supplementation in Infancy. *Pediatrics.* 2018;142(1).

41. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet.* 2010;375(9710):181-183.

42. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. *Eur Heart J.* 2007;28(7):850-856.

43. Stratakis N, Gielen M, Margetaki K, et al. Polyunsaturated fatty acid status at birth, childhood growth, and cardiometabolic risk: a pooled analysis of the MEFAB and RHEA cohorts. *Eur J Clin Nutr.* 2019;73(4):566-576.

44. Kaur G, Guo XF, Sinclair AJ. Short update on docosapentaenoic acid: a bioactive long-chain n-3 fatty acid. *Curr Opin Clin Nutr Metab Care.* 2016;19(2):88-91.

Author Manuscript

This article is protected by copyright. All rights reserved.

45. Ghasemi Fard S, Linderborg KM, Turchini GM, Sinclair AJ. Comparison of the bioavailability of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in the rat. *Prostaglandins Leukot Essent Fatty Acids.* 2014;90(1):23-26.

46. Rump P, Popp-Snijders C, Heine RJ, Hornstra G. Components of the insulin resistance syndrome in seven-year-old children: relations with birth weight and the polyunsaturated fatty acid content of umbilical cord plasma phospholipids. *Diabetologia.* 2002;45(3):349-355.

47. Kennedy K, Ross S, Isaacs EB, et al. The 10-year follow-up of a randomised trial of long-chain polyunsaturated fatty acid supplementation in preterm infants: effects on growth and blood pressure. *Arch Dis Child.* 2010;95(8):588-595.

48. Murff HJ, Edwards TL. Endogenous Production of Long-Chain Polyunsaturated Fatty Acids and Metabolic Disease Risk. *Curr Cardiovasc Risk Rep.* 2014;8(12).

49. Wolters M, Schlenz H, Bornhorst C, et al. Desaturase Activity Is Associated With Weight Status and Metabolic Risk Markers in Young Children. *J Clin Endocrinol Metab.* 2015;100(10):3760-3769.

50. Abe Y, Okada T, Iguchi H, et al. Association of changes in body fatness and fatty acid composition of plasma phospholipids during early puberty in Japanese children. *J Atheroscler Thromb.* 2012;19(12):1102-1109.

Author Manuscript

This article is protected by copyright. All rights reserved.

51. Tosi F, Sartori F, Guarini P, Olivieri O, Martinelli N. Delta-5 and delta-6 desaturases: crucial enzymes in polyunsaturated fatty acid-related pathways with pleiotropic influences in health and disease. *Adv Exp Med Biol.* 2014;824:61-81.

52. Helba M, Binkovitz LA. Pediatric body composition analysis with dual-energy X-ray absorptiometry. *Pediatr Radiol.* 2009;39(7):647-656.

53. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res.* 2008;47(5):348-380.

54. Ripka WL, Orsso CE, Haqq AM, Luz TG, Prado CM, Ulbricht L. Lean mass reference curves in adolescents using dual-energy x-ray absorptiometry (DXA). *PLoS One.* 2020;15(2):e0228646.

55. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. *Am J Epidemiol.* 2005;162(3):267-278.

56. Olivares S, Kain J, Lera L, Pizarro F, Vio F, Moron C. Nutritional status, food consumption and physical activity among Chilean school children: a descriptive study. *Eur J Clin Nutr.* 2004;58(9):1278-1285.

57. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Chile: determinants and consequences. *Public Health Nutr.* 2002;5(1a):123-128.

Author Manuscript

This article is protected by copyright. All rights reserved.

58. Atalah E, Amigo H, Bustos P. Does Chile's nutritional situation constitute a double burden? *Am J Clin Nutr*. 2014;100(6):1623s-1627s.

Author Manuscript

This article is protected by copyright. All rights reserved.

TABLE LEGENDS

Table 1. Changes in BMI-for-age Z scores (BMIZ) [a] from 1 to 16 years of age by serum n-3 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Table 2. Body composition at 16 y of age by serum n-3 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Table 3. Changes in BMI-for-age Z scores (BMIZ)[a] from 1 to 16 years of age by serum n-6 polyunsaturated fatty acid biomarkers and desaturase activity indices at 1 year of age among children from Santiago, Chile

Table 4. Body composition at 16 y of age by serum n-6 polyunsaturated fatty acid biomarkers and desaturase activity indices at 1 year of age among children from Santiago, Chile

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 1. Changes in BMI-for-age Z scores (BMIZ)[a] from 1 to 16 years of age by serum n-3 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	1 y BMIZ (mean ± SE)[b]	16 y BMIZ (mean ± SE)	Change in BMIZ 1 - 16 y (mean ± SE)[b]	Adjusted difference in change (95% CI)[c]
Overall	636	0.81 ± 0.04	0.72 ± 0.05	-0.09 ± 0.05	
N-3					
ALA (18:3 n-3)					
Q1 (0.21)	159	0.81 ± 0.07	0.68 ± 0.09	-0.13 ± 0.11	Reference
Q2 (0.28)	159	0.73 ± 0.07	0.61 ± 0.09	-0.12 ± 0.10	-0.01 (-0.30, 0.27)
Q3 (0.39)	159	0.88 ± 0.08	0.76 ± 0.09	-0.12 ± 0.10	-0.04 (-0.33, 0.25)
Q4 (1.32)	159	0.84 ± 0.08	0.83 ± 0.09	-0.01 ± 0.10	0.06 (-0.24, 0.36)
P, trend[d]				0.33	0.55
EPA (20:5 n-3)					
Q1 (0.07)	159	0.78 ± 0.07	0.65 ± 0.09	-0.12 ± 0.10	Reference
Q2 (0.13)	159	0.80 ± 0.07	0.80 ± 0.09	0.00 ± 0.10	0.10 (-0.18, 0.38)
Q3 (0.22)	159	0.81 ± 0.07	0.77 ± 0.09	-0.05 ± 0.10	0.07 (-0.21, 0.35)
Q4 (0.34)	159	0.86 ± 0.08	0.66 ± 0.09	-0.20 ± 0.11	-0.06 (-0.35, 0.23)
P, trend				0.46	0.56
DPA (22:5 n-3)					
Q1 (0.08)	160	0.78 ± 0.07	0.48 ± 0.09	-0.30 ± 0.09	Reference
Q2 (0.11)	158	0.78 ± 0.07	0.72 ± 0.09	-0.05 ± 0.10	0.23 (-0.04, 0.50)
Q3 (0.14)	159	0.75 ± 0.07	0.98 ± 0.09	0.23 ± 0.10	0.54 (0.26, 0.82)
Q4 (0.21)	159	0.94 ± 0.08	0.71 ± 0.09	-0.24 ± 0.11	0.07 (-0.21, 0.35)
P, trend				0.75	0.71
DHA (22:6 n-3)					
Q1 (0.23)	158	0.84 ± 0.08	0.67 ± 0.10	-0.17 ± 0.10	Reference
Q2 (0.43)	160	0.87 ± 0.06	0.69 ± 0.09	-0.17 ± 0.10	0.05 (-0.23, 0.33)
Q3 (0.62)	159	0.71 ± 0.07	0.72 ± 0.09	0.01 ± 0.10	0.20 (-0.11, 0.50)
Q4 (0.90)	159	0.83 ± 0.08	0.80 ± 0.09	-0.03 ± 0.10	0.17 (-0.16, 0.50)
P, trend				0.19	0.28

Author Manuscript

This article is protected by copyright. All rights reserved.

Footnotes to Table 1

[a] According to the World Health Organization Growth Reference for children ages 5-19 y.[25]

[b] From growth curves estimated using mixed effects linear regression models with BMIZ as the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age slopes to account for within-child correlations of repeated BMI measurements.

[c] Adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), and total serum trans fatty acids (FA). All n-3 PUFA are adjusted for LA and total long-chain n-6 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate FA are represented with linear and restricted cubic spline terms.

[d] From mixed effects linear regression models with BMI as the outcome and a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 2. Body composition[a] at 16 y of age by serum n-3 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	Total fat mass (kg)		Truncal fat mass (kg)		Total lean mass (kg)		% Total fat mass		% Truncal fat mass	
		Mean ± SD	Adjusted difference (95% CI)[b]	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)
Overall	382	19.8 ± 10.1		10.0 ± 5.7		44.0 ± 8.9		29.1 ± 10.9		49.3 ± 5.9	
ALA (18:3 n-3)											
Q1 (0.21)	98	19.5 ± 9.9	Reference	9.8 ± 5.8	Reference	42.8 ± 8.5	Reference	29.4 ± 11.1	Reference	48.7 ± 6.3	Reference
Q2 (0.28)	98	18.4 ± 8.9	-0.4 (-2.7, 2.0)	9.0 ± 4.9	-0.5 (-1.9, 0.9)	43.8 ± 8.4	-0.1 (-1.6, 1.3)	27.8 ± 9.8	-0.2 (-2.3, 1.9)	47.6 ± 5.3	-1.1 (-2.8, 0.5)
Q3 (0.39)	90	19.6 ± 9.3	0.4 (-2.2, 2.9)	9.8 ± 5.3	0.1 (-1.4, 1.6)	45.0 ± 9.8	1.1 (-0.5, 2.7)	28.6 ± 10.2	0.1 (-2.2, 2.4)	49.0 ± 5.9	0.1 (-1.7, 1.9)
Q4 (1.32)	96	21.8 ± 12.0	1.9 (-1.0, 4.7)	11.5 ± 6.5	1.3 (-0.3, 2.9)	44.3 ± 8.8	0.6 (-1.0, 2.2)	30.5 ± 12.3	1.1 (-1.4, 3.5)	51.9 ± 5.0	2.9 (1.2, 4.7)
P, trend[c]		0.05	0.12	0.008	0.03	0.47	0.55	0.21	0.28	<0.0001	<0.0001
EPA (20:5 n-3)											
Q1 (0.07)	95	19.3 ± 11.2	Reference	9.9 ± 6.1	Reference	43.0 ± 8.6	Reference	28.6 ± 11.7	Reference	50.3 ± 5.5	Reference
Q2 (0.13)	95	20.5 ± 9.3	1.1 (-1.4, 3.7)	10.2 ± 5.1	0.1 (-1.3, 1.5)	43.4 ± 8.8	-0.9 (-2.4, 0.6)	30.3 ± 10.0	2.2 (0.1, 4.4)	48.6 ± 5.8	-2.4 (-3.9, -0.8)
Q3 (0.22)	99	19.6 ± 10.3	0.5 (-2.3, 3.3)	10.0 ± 5.9	0.1 (-1.5, 1.7)	45.0 ± 9.4	0.6 (-1.0, 2.2)	28.5 ± 11.2	0.8 (-1.6, 3.2)	49.7 ± 5.7	-1.6 (-3.2, 0.0)
Q4 (0.34)	93	19.8 ± 9.8	-0.1 (-2.7, 2.6)	9.9 ± 5.7	-0.3 (-1.8, 1.2)	44.4 ± 8.7	0.1 (-1.5, 1.6)	28.9 ± 10.7	0.2 (-2.1, 2.5)	48.6 ± 6.3	-2.5 (-4.2, -0.7)
P, trend		0.98	0.74	0.95	0.64	0.19	0.42	0.79	0.62	0.17	0.04
DPA (22:5 n-3)											
Q1 (0.08)	91	17.1 ± 9.0	Reference	8.5 ± 5.1	Reference	43.5 ± 9.0	Reference	26.7 ± 10.7	Reference	48.1 ± 5.9	Reference
Q2 (0.11)	96	20.1 ± 9.8	1.8 (-0.6, 4.2)	10.2 ± 5.5	1.1 (-0.3, 2.5)	42.8 ± 8.5	0.6 (-1.0, 2.1)	30.0 ± 11.0	1.6 (-0.6, 3.8)	49.5 ± 5.5	1.6 (-0.1, 3.3)
Q3 (0.14)	98	21.2 ± 10.7	4.1 (1.4, 6.8)	10.9 ± 6.0	2.4 (0.9, 4.0)	45.7 ± 9.5	1.6 (-0.1, 3.3)	29.7 ± 10.7	3.5 (1.1, 5.9)	50.3 ± 5.7	2.6 (0.8, 4.3)

Author Manuscript

This article is protected by copyright. All rights reserved.

Q4 (0.21)	97	20.6 ± 10.6	2.3	(-0.2, 4.8)	10.4 ± 5.8	1.3	(-0.2, 2.7)	43.8 ± 8.3	0.9	(-0.8, 2.5)	29.9 ± 11.0	1.8	(-0.5, 4.1)	49.2 ± 6.1	1.1	(-0.6, 2.9)
P, trend		0.04	0.10		0.04	0.13		0.48	0.29		0.10	0.15		0.30	0.33	
DHA (22:6 n-3)																
Q1 (0.23)	92	19.1 ± 10.5	Reference		9.7 ± 6.0	Reference		45.3 ± 8.8	Reference		27.7 ± 11.6	Reference		49.2 ± 6.3	Reference	
Q2 (0.43)	100	19.7 ± 9.5	1.1	(-1.6, 3.7)	10.2 ± 5.4	0.7	(-0.8, 2.3)	43.3 ± 8.5	-1.5	(-3.0, 0.0)	29.3 ± 10.7	2.1	(-0.3, 4.6)	50.8 ± 5.3	1.5	(-0.1, 3.1)
Q3 (0.62)	95	20.0 ± 10.6	0.1	(-3.0, 3.2)	10.0 ± 5.9	-0.2	(-2.0, 1.5)	43.7 ± 8.7	0.1	(-1.5, 1.8)	29.4 ± 10.8	0.0	(-2.8, 2.8)	48.8 ± 6.2	-1.1	(-3.1, 0.9)
Q4 (0.90)	95	20.3 ± 10.1	-0.4	(-3.9, 3.2)	10.1 ± 5.5	-0.6	(-2.6, 1.4)	43.6 ± 9.5	-1.0	(-2.8, 0.9)	29.9 ± 10.5	0.2	(-2.8, 3.3)	48.3 ± 5.4	-1.8	(-3.9, 0.3)
P, trend		0.42	0.72		0.77	0.42		0.31	0.54		0.19	0.84		0.06	0.03	

Author Manuscript

This article is protected by copyright. All rights reserved.

Footnotes to Table 2

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-3 PUFA are adjusted for LA and total long-chain n-6 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 3. Changes in BMI-for-age Z scores (BMIZ)[a] from 1 to 16 years of age by serum n-6 polyunsaturated fatty acid biomarkers and desaturase activity indices at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	1 y BMIZ (mean ± SE)[b]	16 y BMIZ (mean ± SE)	Change in BMIZ 1 - 16 y (mean ± SE)[b]	Adjusted difference in change (95% CI)[c]
LA (18:2 n-6)					
Q1 (16.53)	159	0.78 ± 0.07	0.56 ± 0.10	-0.23 ± 0.11	Reference
Q2 (21.31)	159	0.72 ± 0.08	0.79 ± 0.09	0.07 ± 0.10	0.34 (0.03, 0.64)
Q3 (25.87)	159	0.80 ± 0.07	0.74 ± 0.09	-0.06 ± 0.09	0.22 (-0.11, 0.54)
Q4 (30.97)	159	0.95 ± 0.08	0.80 ± 0.09	-0.16 ± 0.10	0.11 (-0.27, 0.49)
P, trend[d]				0.88	0.73
GLA (18:3 n-6)					
Q1 (0.00)	159	0.83 ± 0.07	0.64 ± 0.09	-0.18 ± 0.10	Reference
Q2 (0.07)	159	0.87 ± 0.07	0.79 ± 0.09	-0.07 ± 0.10	0.10 (-0.18, 0.37)
Q3 (0.11)	159	0.81 ± 0.08	0.69 ± 0.10	-0.12 ± 0.11	0.05 (-0.25, 0.35)
Q4 (0.42)	159	0.75 ± 0.08	0.75 ± 0.09	0.00 ± 0.09	0.21 (-0.08, 0.49)
P, trend				0.21	0.18
DGLA (20:3 n-6)					
Q1 (0.44)	159	0.84 ± 0.08	0.68 ± 0.09	-0.16 ± 0.10	Reference
Q2 (0.61)	159	0.74 ± 0.07	0.84 ± 0.09	0.10 ± 0.10	0.25 (-0.03, 0.53)
Q3 (0.76)	159	0.76 ± 0.07	0.73 ± 0.09	-0.03 ± 0.10	0.13 (-0.15, 0.40)
Q4 (0.96)	159	0.90 ± 0.08	0.63 ± 0.10	-0.27 ± 0.11	-0.12 (-0.41, 0.17)
P, trend				0.29	0.28
AA (20:4 n-6)					
Q1 (0.94)	159	0.90 ± 0.07	0.66 ± 0.09	-0.24 ± 0.10	Reference
Q2 (1.31)	159	0.68 ± 0.07	0.68 ± 0.09	0.00 ± 0.10	0.26 (-0.04, 0.56)
Q3 (1.65)	159	0.78 ± 0.07	0.68 ± 0.09	-0.09 ± 0.10	0.22 (-0.10, 0.55)
Q4 (2.27)	159	0.90 ± 0.08	0.86 ± 0.10	-0.04 ± 0.11	0.32 (-0.04, 0.68)
P, trend				0.29	0.13
N-6:N-3 ratio					
Q1 (12.7:1)	159	0.88 ± 0.08	0.78 ± 0.09	-0.10 ± 0.11	Reference
Q2 (18.3:1)	159	0.71 ± 0.08	0.66 ± 0.09	-0.04 ± 0.10	0.06 (-0.22, 0.35)
Q3 (22.9:1)	159	0.81 ± 0.07	0.74 ± 0.10	-0.07 ± 0.10	0.06 (-0.23, 0.35)

Author Manuscript

This article is protected by copyright. All rights reserved.

Q4 (32.0:1)	159	0.85 ± 0.07	0.70 ± 0.09	-0.15 ± 0.09	0.00 (-0.28, 0.29)
P, trend				0.63	0.96
Desaturase activity indices					
Δ6-Desaturase index (GLA/LA)					
Q1 (0.000)	159	0.85 ± 0.08	0.63 ± 0.08	-0.22 ± 0.10	Reference
Q2 (0.003)	159	0.81 ± 0.07	0.84 ± 0.10	0.03 ± 0.11	0.22 (-0.06, 0.50)
Q3 (0.005)	159	0.85 ± 0.07	0.66 ± 0.09	-0.19 ± 0.11	0.02 (-0.27, 0.31)
Q4 (0.017)	159	0.74 ± 0.08	0.76 ± 0.09	0.01 ± 0.09	0.24 (-0.04, 0.52)
P, trend				0.19	0.18
Δ5-Desaturase index (AA/DGLA)					
Q1 (1.57)	159	0.83 ± 0.07	0.63 ± 0.09	-0.20 ± 0.10	Reference
Q2 (1.94)	159	0.76 ± 0.07	0.66 ± 0.09	-0.10 ± 0.10	0.05 (-0.22, 0.33)
Q3 (2.42)	159	0.84 ± 0.07	0.88 ± 0.09	0.04 ± 0.11	0.13 (-0.17, 0.43)
Q4 (3.21)	159	0.83 ± 0.08	0.71 ± 0.09	-0.11 ± 0.10	0.01 (-0.31, 0.32)
P, trend				0.54	0.99

Author Manuscript

This article is protected by copyright. All rights reserved.

Footnotes to Table 3

[a] According to the World Health Organization Growth Reference for children ages 5-19 y.[25]

[b] From growth curves estimated using mixed effects linear regression models with BMI as the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age slopes to account for within-child correlations of repeated BMI measurements.

[c] Adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥ 6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), and total serum trans fatty acids. All n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[d] From mixed effects linear regression models with BMI as the outcome and a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 4. Body composition[a] at 16 y of age by serum n-6 polyunsaturated fatty acid biomarkers and desaturase activity indices at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	Total fat mass (kg)		Truncal fat mass (kg)		Total lean mass (kg)		% Total fat mass		% Truncal fat mass	
		Mean ± SD	Adjusted difference (95% CI)[b]	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)
LA (18:2 n-6)											
Q1 (16.53)	98	19.0 ± 11.3	Reference	9.5 ± 6.1	Reference	43.0 ± 8.4	Reference	28.3 ± 12.1	Reference	49.0 ± 5.8	Reference
Q2 (21.31)	95	20.3 ± 9.2	1.4 (-1.3, 4.1)	10.4 ± 5.4	0.9 (-0.6, 2.5)	43.9 ± 9.0	0.2 (-1.5, 1.9)	29.9 ± 9.7	1.9 (-0.5, 4.2)	49.6 ± 6.1	0.9 (-0.8, 2.6)
Q3 (25.87)	89	19.6 ± 9.8	1.1 (-1.7, 4.0)	9.9 ± 5.5	0.8 (-0.8, 2.3)	45.6 ± 9.0	1.1 (-0.6, 2.8)	28.4 ± 10.8	1.3 (-1.2, 3.8)	49.5 ± 5.8	1.3 (-0.4, 3.1)
Q4 (30.97)	100	20.2 ± 10.2	0.7 (-2.7, 4.1)	10.2 ± 5.7	0.6 (-1.3, 2.5)	43.5 ± 9.0	0.1 (-1.9, 2.1)	29.7 ± 10.8	1.1 (-1.8, 3.9)	49.1 ± 5.8	0.9 (-1.0, 2.9)
P, trend[c]		0.52	0.74	0.54	0.61	0.47	0.73	0.57	0.56	>0.99	0.31
GLA (18:3 n-6)											
Q1 (0.00)	86	18.2 ± 9.0	Reference	9.2 ± 5.1	Reference	44.4 ± 9.2	Reference	27.5 ± 10.5	Reference	49.3 ± 5.9	Reference
Q2 (0.07)	89	19.7 ± 11.1	0.9 (-1.7, 3.5)	10.1 ± 6.2	0.6 (-0.9, 2.0)	44.7 ± 8.7	0.1 (-1.5, 1.7)	28.3 ± 11.8	0.6 (-1.8, 2.9)	50.2 ± 5.7	0.6 (-1.1, 2.3)
Q3 (0.11)	96	20.3 ± 11.0	1.2 (-1.5, 3.8)	10.2 ± 6.1	0.5 (-1.0, 2.1)	43.7 ± 9.3	0.4 (-1.3, 2.1)	29.6 ± 11.3	0.9 (-1.5, 3.3)	49.0 ± 6.4	-0.6 (-2.3, 1.2)
Q4 (0.42)	111	20.7 ± 9.4	2.8 (0.4, 5.2)	10.4 ± 5.3	1.5 (0.2, 2.9)	43.3 ± 8.5	-0.3 (-1.8, 1.3)	30.5 ± 9.9	2.9 (0.7, 5.1)	48.8 ± 5.4	0.7 (-1.0, 2.3)
P, trend		0.13	0.03	0.25	0.03	0.28	0.58	0.04	0.005	0.30	0.38
DGLA (20:3 n-6)											
Q1 (0.44)	89	19.5 ± 10.2	Reference	9.8 ± 5.6	Reference	43.0 ± 9.2	Reference	29.2 ± 11.3	Reference	49.1 ± 5.8	Reference
Q2 (0.61)	98	20.6 ± 9.6	2.0 (-0.7, 4.6)	10.6 ± 5.6	1.3 (-0.2, 2.8)	44.7 ± 8.5	0.8 (-0.6, 2.3)	29.6 ± 10.3	1.9 (-0.4, 4.2)	50.1 ± 5.5	1.3 (-0.3, 2.9)
Q3 (0.76)	94	19.3 ± 10.1	0.5 (-2.0, 3.1)	9.7 ± 5.4	0.4 (-1.0, 1.9)	44.1 ± 8.9	1.1 (-0.5, 2.6)	28.6 ± 10.8	0.4 (-1.8, 2.7)	49.6 ± 5.4	1.3 (-0.4, 2.9)
Q4 (0.96)	101	19.8 ± 10.7	0.6 (-2.2, 3.4)	9.9 ± 6.1	0.4 (-1.2, 1.9)	44.0 ± 9.0	0.5 (-1.2, 2.3)	28.9 ± 11.3	0.3 (-2.1, 2.8)	48.4 ± 6.5	0.1 (-1.7, 1.9)

Author Manuscript

This article is protected by copyright. All rights reserved.

P, trend		0.97	0.99	0.82	0.98	0.63	0.58	0.73	0.83	0.32	0.89
AA (20:4 n-6)											
Q1 (0.94)	87	19.5 ± 9.8	Reference	10.0 ± 5.6	Reference	42.6 ± 8.2	Reference	29.4 ± 10.9	Reference	49.9 ± 5.2	Reference
Q2 (1.31)	107	19.3 ± 9.3	0.2 (-2.6, 3.0)	9.8 ± 5.4	0.1 (-1.5, 1.7)	44.1 ± 9.4	1.3 (-0.4, 2.9)	28.7 ± 10.0	-0.1 (-2.5, 2.4)	49.7 ± 5.8	-0.2 (-1.9, 1.5)
Q3 (1.65)	98	19.0 ± 10.6	-0.2 (-3.3, 2.9)	9.6 ± 5.8	-0.3 (-2.0, 1.5)	44.3 ± 8.8	1.2 (-0.6, 2.9)	28.0 ± 11.8	-0.7 (-3.3, 1.9)	49.0 ± 6.3	-1.0 (-2.8, 0.8)
Q4 (2.27)	90	21.5 ± 10.8	1.1 (-2.7, 5.0)	10.7 ± 6.0	0.4 (-1.6, 2.5)	44.7 ± 8.9	0.2 (-1.9, 2.3)	30.4 ± 10.9	1.6 (-1.5, 4.7)	48.6 ± 6.0	-1.1 (-3.2, 1.0)
P, trend		0.18	0.57	0.37	0.72	0.12	0.87	0.47	0.31	0.09	0.23
N-6:N-3 ratio											
Q1 (12.7:1)	91	20.8 ± 10.9	Reference	10.9 ± 6.1	Reference	43.5 ± 8.6	Reference	30.1 ± 11.4	Reference	51.4 ± 5.5	Reference
Q2 (18.3:1)	98	18.6 ± 9.5	-0.9 (-3.4, 1.7)	9.2 ± 5.2	-1.0 (-2.5, 0.4)	44.5 ± 8.4	-0.1 (-1.6, 1.3)	27.8 ± 10.5	-0.3 (-2.5, 1.8)	47.8 ± 5.5	-3.4 (-5.0, -1.8)
Q3 (22.9:1)	94	20.6 ± 10.6	0.6 (-2.2, 3.4)	10.4 ± 5.9	0.0 (-1.7, 1.6)	44.9 ± 10.2	1.5 (-0.1, 3.0)	29.5 ± 10.8	0.1 (-2.2, 2.5)	49.2 ± 5.8	-2.1 (-3.7, -0.4)
Q4 (32.0:1)	99	19.3 ± 9.5	-0.1 (-2.6, 2.5)	9.7 ± 5.4	-0.3 (-1.8, 1.2)	42.9 ± 8.2	-0.9 (-2.5, 0.7)	29.1 ± 10.9	0.6 (-1.7, 2.9)	49.0 ± 6.0	-1.8 (-3.4, -0.2)
P, trend		0.52	0.81	0.38	>0.99	0.46	0.40	0.85	0.51	0.06	0.20
Desaturase activity indices											
Δ6-Desaturase index (GLA/LA)											
Q1 (0.000)	92	18.2 ± 8.8	Reference	9.2 ± 5.0	Reference	44.0 ± 9.3	Reference	27.7 ± 10.3	Reference	49.5 ± 5.8	Reference
Q2 (0.003)	82	20.6 ± 11.2	1.2 (-1.4, 3.9)	10.5 ± 6.2	0.7 (-0.8, 2.2)	44.7 ± 9.2	0.2 (-1.4, 1.8)	29.4 ± 11.7	1.1 (-1.3, 3.5)	49.8 ± 5.9	0.1 (-1.6, 1.8)
Q3 (0.005)	96	19.0 ± 10.9	0.8 (-1.8, 3.4)	9.5 ± 5.9	0.3 (-1.2, 1.8)	44.5 ± 8.5	0.3 (-1.2, 1.8)	27.8 ± 11.5	0.4 (-1.9, 2.8)	48.7 ± 6.4	-0.9 (-2.6, 0.9)
Q4 (0.017)	112	21.2 ± 9.6	3.1 (0.7, 5.5)	10.7 ± 5.5	1.7 (0.3, 3.1)	42.8 ± 8.6	-0.2 (-1.8, 1.4)	31.2 ± 10.0	3.1 (1.0, 5.3)	49.2 ± 5.4	0.7 (-0.8, 2.3)
P, trend		0.06	0.01	0.10	0.02	0.16	0.64	0.01	0.003	0.71	0.23

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

Δ5-Desaturase index (AA/DGLA)											
Q1 (1.57)	102	19.0 ± 10.1	Reference	9.7 ± 5.7	Reference	43.9 ± 8.3	Reference	28.1 ± 10.9	Reference	49.9 ± 5.5	Reference
Q2 (1.94)	97	18.9 ± 9.0	-0.6 (-3.1, 1.8)	9.6 ± 5.3	-0.5 (-1.9, 1.0)	44.0 ± 9.5	0.5 (-1.1, 2.0)	28.4 ± 10.5	-0.4 (-2.7, 1.9)	49.3 ± 6.2	-1.2 (-2.8, 0.4)
Q3 (2.42)	96	21.4 ± 11.0	0.4 (-2.3, 3.1)	10.9 ± 6.1	0.2 (-1.4, 1.7)	44.0 ± 9.4	0.3 (-1.3, 1.9)	30.7 ± 11.3	0.3 (-2.1, 2.7)	49.4 ± 5.8	-1.0 (-2.7, 0.7)
Q4 (3.21)	87	19.9 ± 10.3	-0.7 (-3.8, 2.4)	9.8 ± 5.6	-0.6 (-2.4, 1.1)	43.8 ± 8.4	-0.6 (-2.3, 1.1)	29.2 ± 10.7	-0.3 (-2.9, 2.4)	48.4 ± 5.8	-1.9 (-3.8, -0.1)
P, trend		0.35	0.78	0.61	0.57	0.93	0.38	0.32	0.93	0.08	0.07

This article is protected by copyright. All rights reserved.

Footnotes to Table 4

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript



For the best experience, open this PDF portfolio in Acrobat X or Adobe Reader X, or later.

Get Adobe Reader Now!

This article is protected by copyright. All rights reserved.

Serum polyunsaturated fatty acids in infancy are associated with body composition in adolescence

Kerry Flannagan[1], Sheila Gahagan[2], Arun Das[3],

Raquel Burrows[4], Betsy Lozoff[5], and Eduardo Villamor[1]

[1]Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; [2]Division of Child Development and Community Health, University of California, San Diego, CA, USA; [3]Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; [4]Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile; [5]Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI, USA.

Keywords: polyunsaturated fatty acids; body composition; body mass index; children; infants; Chile

Running title: Polyunsaturated fatty acids and body composition

Address correspondence to: E Villamor, Department of Epidemiology, University of Michigan School of Public Health, 1420 Washington Heights, SPH II, Room M5507, Ann Arbor, MI 48109; Tel: 734-615-2198; Fax: 734-764-3192; Email: villamor@umich.edu.

Author Manuscript

This article is protected by copyright. All rights reserved.

Abbreviations: PUFA, polyunsaturated fatty acids; IDA, iron deficiency anemia; FA, fatty acids; INTA, University of Chile Institute of Nutrition and Food Technology; DXA, dual energy X-ray absorptiometry; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; LA, linoleic acid; GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; AA, arachidonic acid; D6D, Δ6-desaturase; D5D, Δ5-desaturase; BMI, body mass index; ToFM, total fat mass; TrFM, truncal fat mass; TLM, total lean mass; %ToFM, percent total fat mass; %TrFM, percent truncal fat mass; SES, socioeconomic status; CI, confidence interval; BMIZ, BMI-for-age Z score

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

ABSTRACT

Background: Polyunsaturated fatty acids (PUFA) have been related to the development of adiposity. N-3 PUFA appear to be protective against obesity risk, while n-6 PUFA may be associated with greater adiposity. However, most studies have been conducted among adults. The role of PUFA in infancy is unknown.

Objective: To examine associations of serum PUFA at age 1 y with age- and sex-adjusted body mass index Z score (BMIZ) change through age 16 y and body composition at 16 y.

Methods: We quantified serum PUFA in 636 Chilean infants aged 1 y. We measured BMIZ at ages 1, 5, 10, and 16 y, and body composition by dual energy X-ray absorptiometry at 16 y. We estimated differences in 1- to 16-y BMIZ change between PUFA quartiles from multivariable linear mixed models with restricted cubic splines. At 16 y, we estimated differences in total fat mass (ToFM), truncal fat mass (TrFM), total lean mass (TLM), percent total fat mass (%ToFM), and percent truncal fat mass (%TrFM) between PUFA quartiles using linear regression.

Results: PUFA were not associated with BMIZ change. Alpha-linolenic acid (ALA) was positively associated with TrFM (P=0.03) and %TrFM (P<0.0001) at 16 y while eicosapentaenoic acid (EPA) was inversely associated with %TrFM (P=0.001). Docosapentaenoic acid (DPA) was positively associated with ToFM (P=0.01), TrFM (P=0.009), %ToFM (P=0.02), and %TrFM (P=0.02). Gamma-linolenic acid (GLA) and the Δ6-desaturase (D6D) activity index were each positively, linearly associated with ToFM, TrFM, and %ToFM. The Δ5-desaturase (D5D) activity index was inversely associated with %TrFM (P=0.04).

Conclusions: ALA, DPA, GLA, and the D6D index at 1 y of age were positively associated with adiposity at age 16 y, while EPA and the D5D index were inversely associated with central

This article is protected by copyright. All rights reserved.

adiposity. Our results related to EPA and desaturase indices are in agreement with limited prior studies.

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

INTRODUCTION

Childhood obesity is the most prevalent early life risk factor for the development of chronic diseases, including type 2 diabetes, hypertension, and coronary heart disease.[1] Childhood obesity has increased globally throughout recent decades[2] and represents a significant public health concern. Identifying potentially modifiable nutritional exposures that influence the early development of adiposity is crucial in order to address this epidemic.

Polyunsaturated fatty acids (PUFA) are nutrients that may be related to the etiology of obesity. These fatty acids (FA), primarily classified into the n-3 and n-6 families, are necessary for a variety of physiologic processes. In particular, long-chain PUFA are precursors for eicosanoids, signaling molecules that regulate cardiovascular and immune function. In animal and *in vitro* studies, both plant- and marine-derived n-3 PUFA reduce or prevent adiposity, through reduction of fat deposition in adipose tissue and appetite suppression.[3,4] Conversely, n-6 PUFA upregulate adipocyte size and number.[5] Studies of PUFA and adiposity among adult humans have yielded mixed results. Some, but not all, trials of n-3 PUFA supplementation have found an inverse effect on adiposity.[6] While several observational studies (reviewed by Naughton et al[7]) report a positive association between the n-6 PUFA linoleic acid (18:2 n-6; LA) and body weight, a meta-analysis of n-6 PUFA supplementation trials did not find strong evidence for an effect of these PUFA on adiposity.[8]

PUFA status in infancy may be particularly influential on future adiposity. The precursor PUFA alpha-linolenic acid (18:3 n-3; ALA) and LA cannot be synthesized endogenously, and their conversion into long-chain PUFA is inefficient in humans.[9] Thus infants must largely obtain these FA through diet, initially from breast milk or formula[10] and later through complementary feeding. Nutrition during infancy can have long-term effects on cardiovascular

This article is protected by copyright. All rights reserved.

health.[11] Adipose tissue in childhood may be especially sensitive to the effects of PUFA, since this is the time during which the number of adipocytes in the body is determined.[12] Most previous investigations of early-life PUFA and adiposity have focused on exposure *in utero*.[13] The potential effects of PUFA in infancy may differ from those *in utero,* but results from previous studies have been inconclusive, and little research exists on measures of long-term adiposity. In a recent review of both observational studies and trials of n-3 PUFA supplementation in infancy, results were a mix of positive, inverse, and null associations of specific PUFA with measures of adiposity through middle childhood.[13] In addition to these inconclusive findings, the outcomes in these studies were assessed at ages 6-8 y, and thus it is still unclear whether PUFA might have longer-reaching effects on adiposity throughout development. Moreover, very few studies have been conducted in low- and middle-income countries,[14-16] despite the rapidly growing burden of childhood obesity[2] and low availability of dietary PUFA[17] affecting many of these regions.

We aimed to investigate the relations between serum PUFA biomarkers at 1 y of age and measures of adiposity at age 16 y in a cohort of children from Santiago, Chile.

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

METHODS

Study design and population. We conducted a longitudinal investigation among Chilean children who were enrolled as infants in studies on iron status and were followed through adolescence. Details of the study design have been published previously.[18,19] Briefly, participants were recruited at ages 4-6-months from low- and middle-income communities in Santiago, Chile between 1991 and 1996. Eligible infants were singleton, born at term weighing at least 3 kg through uncomplicated, vaginal births, and did not have major health complications. Infants without iron deficiency anemia (IDA) at baseline were enrolled in a trial of iron supplementation. These participants were randomly assigned to high- or low-dose iron supplementation or usual nutrition until 12 months of age. Infants with IDA were treated with iron and enrolled in an observational study of neurodevelopment, along with a group of non-anemic controls. There were 1798 infants enrolled; of these, 1657 completed the trial and 135 were in the neurodevelopment study at 6 months. The cohort was followed during middle childhood and adolescence: 888 children were assessed at 5 y of age, 1127 at 10 y of age, and a subset of 679 were assessed at a mean age of 16.8 y of age as part of a study on cardiometabolic risk.[20] The study of FA was conducted among participants who had a stored serum sample available from age 1 y plus at least one more sample from ages 5 or 10 y. For analyses of BMIZ change between 1 and 16 y of age, we included 636 children in the FA study who had BMIZ data available at 1 y of age and at $\geq$ 1 subsequent assessment (5, 10, or 16 y of age). For the analysis of PUFA at 1 y of age and DXA measures of body composition at 16 y of age, there were 382 children with available information. A flowchart of the sample size at each inclusion step is provided in **Figure S1**.

This article is protected by copyright. All rights reserved.

The study procedures were approved by institutional review boards at the University of Chile Institute of Nutrition and Food Technology (INTA), the University of Michigan, and the University of California, San Diego. Parents provided written informed consent to participate for their children, and children provided written assent beginning at 10 y of age.

Data collection. Birth weight in g, length in cm, and gestational age in weeks were determined via hospital records. The date of the mother's last menstrual period was used to determine gestational age. Study personnel collected information from parents on household socioeconomic indicators at enrollment. Information on breastfeeding habits, including the date of the first bottle feeding and last breastfeeding, were collected from mothers at weekly study visits that took place from enrollment until the infant was 12 months old. For infants who had already been bottle fed at enrollment, mothers were asked to recall the date of the first bottle feeding. Because feeding breast milk by bottle was nonexistent in this population, bottle feeding was equivalent to giving infant formula or cow milk.

Anthropometric measurements were collected at INTA by trained study personnel using standardized techniques. At 1 y of age, weight was measured unclothed to the nearest 10 g and length was measured to the nearest millimeter using a recumbent length board. Weight at 5, 10 and 16 y was measured to the nearest 100 g using a Seca scale (Seca, Hamburg, Germany) and height was measured to the nearest millimeter using a Holtain stadiometer (Holtain, Crymych, UK). All measures were obtained in duplicate and a third measurement was taken if the difference between the first two was greater than 0.3 kg or 0.5 cm; the mean of the two closest values was used. At the 16.8 y assessment, total fat mass, truncal fat mass, and total lean mass were measured with a dual energy X-ray absorptiometry (DXA) instrument (Lunar Prodigy

Author Manuscript

This article is protected by copyright. All rights reserved.

Corp., Madison, WI, USA). These measures were conducted in the subset of children who participated in the study of cardiometabolic risk.

A blood sample was collected by venipuncture at 1, 5 and 10 y of age. The median (25^{th}, 75^{th} percentile) age at the 1 y blood draw was 1.00 y (0.99, 1.02). Blood components were separated and serum samples from 1 y of age were stored at -80˚C before transportation as a single batch to the University of Michigan where they were cryostored at -80˚C and analyzed after approximately 20 y from collection. Serum PUFA stored at -80˚C are highly stable. A previous study found virtually no degradation of PUFA in samples stored at -80˚C for up to 10 years.[21]

Fatty acid analyses. FA in serum were quantified at the University of Michigan Regional Comprehensive Metabolomics Resource Core. Total lipids were extracted from 200 μl of serum according to the method described by Bligh and Dyer.[22] 10 μL of 4 mM nonadecanoic acid (C19:0) was used as the internal standard. The FA fraction of the total lipids was derivatized into methyl esters using BF_3-methanol as previously described.[23] These were extracted with a 2:1 hexane-water, dried, and resuspended in hexane. FA were measured using gas chromatography. 1-2 μL of sample was injected via autosampler onto an Agilent 6890N chromatograph (Agilent, Santa Clara, CA, USA) with a flame ionization detector, a 100 m x 0.25 mm x 0.2 μm SP-2560 column (Sigma-Aldrich, Bellefonte, PA, USA) and Chemstation software. C19:0 and other authentic methyl esters were used to create a calibration curve for FA quantification. The authentic methyl esters were also used to identify FA in samples based on retention times. The coefficients of variation for quantification of specific FA ranged between 2.5-3.6%.

Statistical Analyses. *Definition of exposures*. The main exposures were serum PUFA biomarkers measured at 1 y of age, expressed as percentage relative to the total FA concentration

This article is protected by copyright. All rights reserved.

Author Manuscript

(FA %) quantified in a sample. The n-3 PUFA we considered were ALA, eicosapentaenoic acid (20:5 n-3; EPA), docosapentaenoic acid (22:5 n-3; DPA), and docosahexaenoic acid (22:6 n-3; DHA). N-6 PUFA included LA, gamma-linolenic acid (18:3 n-6; GLA), dihomo-gamma-linolenic acid (20:3 n-6; DGLA), and arachidonic acid (20:4 n-6; AA). We also considered the ratio of total n-6:n-3 PUFA, which may be important for adiposity development.[24] Additionally, we considered activity indices of the Δ6-desaturase (D6D) and Δ5-desaturase (D5D) enzymes, using the GLA/LA and AA/DGLA ratios, respectively. We categorized all exposures into quartiles to allow for possible non-linear associations with the outcomes.

Definition of outcomes. The primary outcomes were change in age- and sex-adjusted body mass index (BMI) Z scores (BMIZ) between 1 and 16 y of age and DXA measures of body composition at 16 y of age. BMI was calculated as kg/m^2 and BMIZ were calculated according to the World Health Organization Growth Reference for children ages 5-19 y.[25] DXA measures included the total fat mass (ToFM), truncal fat mass (TrFM), total lean mass (TLM), percent total fat mass (%ToFM), and percent truncal fat mass (%TrFM).

Covariates. All covariates were measured in infancy and included sociodemographic and anthropometric characteristics as well as serum FA. We categorized birth length and weight as average or large for gestational age according to the INTERGROWTH 21st standards for newborn size.[26] We defined large for gestational age as ≥90th percentile. We did not consider a category of small for gestational age because birth weight ≥3 kg was an eligibility criterion for recruitment and there were no children ≤10th percentile for birth weight. Seven children with birth length ≤10th percentile were classified in the average for gestational age group. We categorized breastfeeding as <6 months, ≥6 months mixed bottle/breastfeeding, or ≥6 months exclusive breastfeeding. Iron supplementation was categorized as any (combining low- and high-

This article is protected by copyright. All rights reserved.

Author Manuscript

dose groups) vs. none. We measured socioeconomic status (SES) using a modified Graffar index.[27] The index consists of 13 items related to family structure, education and employment, crowding and housing condition, and ownership of assets. The index ranges from 0 to 65; higher values indicate lower SES. The serum FA that we considered as covariates were total *trans* FA, which have been associated with weight gain in adults.[28]

Correlates of serum PUFA at 1 y of age. We compared distributions of serum PUFA biomarkers by categories of covariates using means ± SD. We tested the significance of associations using linear regression models with each PUFA biomarker as the outcome. For dichotomous covariates, we obtained P values from Wald tests. For ordinal variables, we tested for linear trends using Wald tests of a variable representing category-specific medians introduced as a continuous variable. For categorical covariates, we used a χ^2 score statistic. We specified robust estimates of variance in all models.

Serum PUFA at 1 y of age and change in BMIZ from ages 1 to 16 y. In bivariate analysis, we estimated means ± SE of BMIZ at 1 and 16 y of age and change in BMIZ between 1 and 16 y by quartiles of the PUFA exposures at age 1 y. These were from BMIZ growth curves estimated using mixed effects linear regression models.[29] The outcome was BMIZ and age was represented as a predictor using restricted cubic splines.[30] These piecewise cubic polynomials are smoothly joined at each knot and linear in the tails. They allow for modeling of smoothed, non-linear trajectories of BMIZ across different ages. These methods do not require that all children have the same number of measurements or that the measurements be obtained at the same ages. Thus, we fitted the models with data from all assessments (1, 5, 10, and 16 y) and placed knots at the median ages of children measured at each assessment. Other predictors in the model included indicator variables for each PUFA quartile, interaction terms between the PUFA indicators and

This article is protected by copyright. All rights reserved.

Author Manuscript

all age terms, and random intercepts and age slopes for each child. We estimated adjusted mean differences and 95% confidence intervals (CI) in 1 to 16 y BMIZ change between quartiles of serum PUFA from these models. We included covariates that were associated with the PUFA biomarkers or that have been related to BMIZ change. The final model included sex, birth weight, breastfeeding, Graffar index, and total serum *trans* FA at 1 y of age. Each long-chain PUFA was adjusted for its immediate metabolic precursor: EPA was adjusted for ALA, DPA for EPA, DHA for DPA, GLA for LA, DGLA for GLA, and AA for DGLA. In order to adjust for potential confounding by common dietary sources of n-3 and n-6 PUFA, which co-occur as LA and ALA in foods such as plant oils,[31] we adjusted estimates for each n-3 PUFA for LA and total long-chain n-6 PUFA, while estimates for each n-6 PUFA were adjusted for ALA and total long-chain n-3 PUFA. All covariate FA were entered in the model as restricted cubic splines in order to account for possible residual confounding due to non-linear associations with the outcome. When the association between PUFA quartiles and BMIZ change seemed linear, we estimated the difference in change per 1 SD of the PUFA distribution.

Serum PUFA at 1 y of age and body composition at 16 y. In bivariate analysis, we compared distributions of ToFM, TrFM, TLM, %ToFM, and %TrFM by quartiles of serum PUFA using means ± SD. We conducted tests for linear trend using linear regression models with each body composition measure as the outcome and a variable representing median values of each PUFA quartile introduced as a continuous variable. In multivariable analysis we obtained adjusted mean differences and 95% CI in the body composition measures by quartiles of serum PUFA. These models included indicators for PUFA quartiles and were also adjusted for sex, birth weight, breastfeeding, Graffar index, BMI at 1 y of age, and total serum *trans* FA. We also included other PUFA as covariates following the strategy described for the analyses of BMIZ

This article is protected by copyright. All rights reserved.

Author Manuscript

change. Because body composition may differ by sex in adolescence, we conducted supplemental analyses stratified by sex by including interaction terms between sex and all other model predictors and testing for their statistical significance.

We fitted all models with empirical variance estimates, which are robust to heteroskedasticity and deviations from normality.[32] All analyses were conducted using Statistical Analysis Software version 9.4 (SAS Institute, Cary, NC, USA).

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

RESULTS

The number of children with 2, 3, or 4 measurements was 78, 183, and 375, respectively. Mean ± SD BMIZ at 1, 5, 10, and 16 y of age was 0.81 ± 0.94, 0.98 ± 1.18, 1.02 ± 1.16, and 0.71 ± 1.13, respectively. At age 16 y, mean ± SD ToFM, TrFM, and LM was 19.8 ± 10.1, 10.0 ± 5.7, and 44.0 ± 8.9 kg, respectively. Mean ± SD %ToFM and %TrFM was 29.1 ± 10.9 and 49.3 ± 5.9.

N-3 PUFA

Correlates of n-3 PUFA at 1 y. Serum ALA was positively associated with iron supplementation (**Table S1**). EPA was positively related to exclusive breastfeeding duration and total *trans* FA. DPA was inversely associated with iron supplementation. DHA was related to female sex and exclusive breastfeeding duration, and inversely associated with total serum *trans* FA.

BMIZ change between ages 1 and 16 y. N-3 PUFA at 1 y of age were not significantly associated with BMIZ change from 1 to 16 y (**Table 1 and Table S2**).

Body composition at age 16 y. ALA was positively associated with TrFM and %TrFM in non-linear fashions (**Table 2 and Table S2**). Adjusted mean differences (95% CI) between children with ALA in quartile (Q) 4 vs. <Q4 were 1.5 kg (0.2, 2.8; P=0.03) for TrFM and 3.3 percentage points (95% CI: 2.0%, 4.6%; P<0.0001) for %TrFM. EPA was inversely associated with %TrFM (adjusted mean difference >Q1 vs. Q1: -2.1%; 95% CI: -3.5%, -0.9%; P=0.001). DPA was positively associated with fat mass indices in non-linear manners. Adjusted mean differences (95% CI) between DPA >Q1 vs. Q1 for ToFM, TrFM, %ToFM, and %TrFM were, respectively, 2.7 kg (95% CI: 0.7, 4.8; P=0.01), 1.6 kg (95% CI: 0.4, 2.8; P=0.009), 2.3% (95% CI: 0.4, 4.2; P=0.02), and 1.8% (95% CI: 0.3, 3.2; P=0.02). Most associations did not differ by

This article is protected by copyright. All rights reserved.

sex (**Table S3 and Table S4**). However, the positive association of ALA with %TrFM was stronger among boys (*P*, interaction=0.02), as was the inverse association of EPA with %TrFM (*P*, interaction=0.004).

N-6 PUFA

Correlates of n-6 PUFA at 1 y. LA was positively associated with exclusive breastfeeding ≥6 months and with iron supplementation (**Table S5**). It was inversely associated with total *trans* FA. Serum GLA was inversely related to length-for-gestational age and socioeconomic status. DGLA was positively associated with length- and weight-for-gestational age and inversely related to iron supplementation. AA was positively associated with length- and weight-for-gestational age, and exclusive breastfeeding ≥6 months, and inversely related to iron supplementation and total *trans* FA. The n-6:n-3 ratio was inversely associated with total *trans* FA. The D6D index was inversely associated with length-for-gestational age and socioeconomic status.

BMIZ change between ages 1 and 16 y. Neither n-6 PUFA, the n-6:n-3 ratio, nor desaturase indices at 1 y of age was significantly associated with change in BMIZ (**Table 3 and Table S6**).

Body composition at 16 y of age. Without adjustment for n-3 PUFA, GLA (*P*, trend=0.02) and the D6D index (*P*, trend=0.01) were each positively associated with %ToFM (**Table S6**). In fully adjusted models, GLA and the D6D index were each positively, linearly associated with ToFM, TrFM, and %ToFM (**Table 4**). Every 1 SD (0.36) difference in GLA was associated with an adjusted higher mean ToFM (1.0 kg per SD; 95% CI: 0.1, 1.9; *P*=0.03), TrFM (0.6 kg per SD; 95% CI: 0.1, 1.1; *P*=0.03), and %ToFM (1.0 percentage points per SD; 95% CI: 0.2%, 1.7%; *P*=0.01). A 1 SD difference (0.02) in the D6D index was related to a higher mean

Author Manuscript

This article is protected by copyright. All rights reserved.

ToFM (1.2 kg per SD; 95% CI: 0.0, 2.3; *P*=0.04), TrFM (0.7 kg per SD; 95% CI: 0.0, 1.4; *P*=0.05), and %ToFM (1.1 percentage points per SD; 95% CI: 0.2%, 2.1%; *P*=0.02). The D5D index was inversely associated with %TrFM. Children in the highest quartile had a mean %TrFM 1.9 percentage points lower than did children in the lowest quartile (95% CI: -3.8%, -0.1%; *P*=0.04). A slight inverse association between DGLA and %TrFM was present only among girls (*P*, interaction=0.02); no other associations differed by sex (**Table S7 and Table S8**).

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

DISCUSSION

In this longitudinal study of Chilean children, PUFA at 1 y of age were not associated with BMIZ changes through childhood and adolescence. Nevertheless, they were related to body composition at age 16 y. Serum ALA at 1 y of age was positively associated with TrFM and %TrFM at 16 y. EPA was inversely associated with %TrFM, while DPA was positively associated with ToFM, TrFM, %ToFM, and %TrFM. GLA and the D6D index were each positively associated with ToFM, TrFM, and %ToFM. The D5D index was inversely associated with %TrFM.

Serum ALA was positively associated with truncal fat. This is in contrast to a previous study in which maternal plasma ALA during pregnancy was inversely associated with the android/gynoid fat mass ratio and pre-peritoneal fat mass area in offspring at 6 y of age.[33] One potential explanation for this discrepancy is the difference in ages at which body composition was measured in the two studies. Body composition may not track completely between childhood and adolescence. Thus, the relation between early-life ALA and body composition at 6 y of age may be different than its relation with body composition at 16 y. Other possible explanations include the differences in timing of exposure assessment, measures of central adiposity, or ALA intake between the study populations. Four other studies of early-life ALA exposure and measures of adiposity have used BMI as an outcome, which does not distinguish between fat compartments. None of these found associations between ALA in cord blood[34,35] or breastmilk[15,36] with BMI during infancy or childhood, consistent with our finding of no association with BMI change. The mechanism underlying a potential effect of ALA on central adiposity is unclear. One possibility is that much of the serum ALA measured in these children could have been *trans* ALA. In areas where hydrogenated oils are present in the food supply,

This article is protected by copyright. All rights reserved.

trans ALA represents a large proportion of total dietary ALA.[37] Chile had not banned *trans* FA from its food supply at the time of FA measurement in this study.[38] Although few studies have investigated the health effects of *trans* ALA, other *trans* FA have been positively associated with central adiposity.[39] We did not measure *trans* isomers of ALA and could not differentiate its effects from those of *cis* ALA. The association could also be due to confounding by unmeasured aspects of diet.

We found that EPA was inversely associated with %TrFM. In a randomized trial, supplementation with EPA+DHA from birth to 6 months resulted in lower waist circumference at 5 y of age.[40] In another study, maternal plasma EPA during pregnancy was inversely associated with the android/gynoid fat mass ratio and pre-peritoneal fat mass area at 6 y.[33] Previous studies of EPA during pregnancy, in cord blood, or in breastmilk have not consistently found protective associations with measures of overall adiposity such as BMI and %ToFM.[13] However, our results and others suggest that EPA may be specifically protective against central adiposity, which is related to development of the metabolic syndrome[41] and cardiovascular disease.[42] Whether early-life EPA decreases risk of future chronic disease remains to be investigated.

DPA at age 1 y was positively associated with ToFM, TrFM, %ToFM, and %TrFM at 16 y. In a pooled analysis of two large cohorts, cord blood DPA was not associated with childhood BMI.[43] Maternal DPA during pregnancy was inversely associated with %ToFM and the android/gynoid fat mass ratio at 6 y in a Dutch study.[33] Compared with EPA, DPA is found at lower levels in the diet[44] and may be less bioavailable.[45] Thus, DPA in serum could more closely reflect endogenous activity of D6D than it does DPA intake. Associations between DPA and fat mass might reflect associations with D6D activity rather than an effect of DPA itself.

This article is protected by copyright. All rights reserved.

Author Manuscript

GLA was positively associated with ToFM, TrFM, and %ToFM. This is in agreement with an investigation that reported a positive association between maternal plasma GLA during pregnancy and %ToFM and pre-peritoneal fat mass area in offspring at age 6 y.[33] However, two other studies found no association between cord blood GLA and BMI or %ToFM in childhood.[43,46] A trial of formula supplemented with GLA+DHA until 9 months of age found no effect on BMI or %ToFM at age 10 y.[47] Differences among studies may be the result of differences in GLA levels between populations, or effect modification by desaturase gene variations.[48]

Estimated D6D enzyme activity was positively associated with ToFM, TrFM, and %ToFM, while the D5D index was inversely associated with %TrFM. Our results are consistent with two longitudinal studies conducted among children aged 2-10 y[49] and 10 y,[50] and evidence that cardiometabolic risk factors are positively related to D6D activity and inversely associated with D5D activity among adults.[51]

Although PUFA in infancy were related to body composition in adolescence, they were not associated with BMIZ trajectories. These results are unexpected since BMI and BMIZ correlate with fat mass throughout childhood. One possible explanation is that the differences in body composition at 16 y by PUFA concentrations may already have been present at 1 y. We tried to overcome this possibility by adjusting the analyses of body composition measures at age 16 y for BMI at 1 y, but BMI in infancy is an imperfect proxy for fat mass. Another possibility is that the outcomes measured by DXA are more precise measures of adiposity than BMIZ, which reflects both fat and lean mass, or that the effects of PUFA differ between body fat compartments, which are not separated by using BMIZ.

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

One of the primary strengths of this study is its longitudinal design, which limits the possibility of reverse causation. We had an opportunity to examine associations of early-life exposures with outcomes at older ages, which provides evidence for the relevance of PUFA status in infancy for long-term health. PUFA biomarkers are not subject to errors in recall or food composition tables, as opposed to dietary assessment data. Furthermore, we assessed body composition using DXA, which provides reliable and valid measures of fat and lean mass.[52]

One of the limitations of this study is that serum PUFA biomarkers reflect status over a period of weeks and may misclassify participants with respect to long-term intake.[53] Analyses of multiple exposures could have increased type I error. Body composition measures differ by sex in adolescence[54]; although interactions by sex were not statistically significant, effect modification by sex cannot be completely ruled out. The lack of available body composition measurements in infancy prevented us from analyzing change in these outcomes or adjusting for their baseline values. Adiposity at 1 y of age could have influenced serum PUFA levels at 1 y of age, and this reverse causation may have influenced the results related to BMIZ trajectories. However, we chose not to adjust for baseline BMIZ in these analyses because this adjustment can cause bias.[55] Measured baseline BMIZ is the result of both true baseline BMIZ and its measurement error, which in turn contributes to measured BMIZ change from baseline to 16 y, the outcome of interest. As a common effect of two variables (a “collider”), baseline BMIZ naturally blocks the flow of a non-causal statistical association between the exposure (PUFA) and the outcome. Adjusted for baseline BMIZ could unblock such a non-causal path and induce a spurious association between PUFA and BMIZ change from baseline to later ages. Finally, because we only had relative measures of serum PUFA expressed as a percentage of total FA, we were unable to determine the extent to which differences in PUFA FA percentage reflect

This article is protected by copyright. All rights reserved.

differences in absolute serum PUFA content or serum levels of saturated, monounsaturated, and *trans* FA.

In conclusion, serum ALA and DPA at 1 y of age were positively associated with measures of fat mass at age 16 y, whereas EPA was inversely associated with %TrFM. GLA and the D6D index were also positively associated with adiposity in adolescence, while D5D activity was inversely related to this outcome. PUFA status in infancy might affect long-term body composition and adiposity. Our results could be generalizable to other populations with similar dietary intake and behavior, which in this Chilean population have been characterized as low in fruits and vegetables, high in snack foods with saturated fat and refined carbohydrates, and low in physical activity levels.[56] Our results may also be applicable to populations undergoing a similar nutrition transition. In Chile, economic growth in the 1990s resulted in one of the most rapid transitions in Latin America, including a shift toward Western diets and sedentary lifestyles.[57] By the time of the 16 y follow-up in our study, the transition was advanced with a very low prevalence of stunting and high prevalence of obesity.[58] Intervention studies are warranted to elucidate the potential protective effect of EPA against the development of central adiposity in children and adolescents.

Author Manuscript

This article is protected by copyright. All rights reserved.

CONFLICT OF INTEREST STATEMENT

The authors report no conflicts of interest.

Author Manuscript

This article is protected by copyright. All rights reserved.

ACKNOWLEDGMENTS

EV, SG, and BL designed the research. SG, BL, and AD conducted the research. KF performed the data analysis. KF and EV wrote the paper and had primary responsibility for the final content. All authors read and approved the final manuscript.

The study was funded by grants HL117860, HD033487, and HL088530 from the National Institutes of Health. Fatty acids were quantified using Core Services supported by grant DK097153 from the National Institutes of Health to the University of Michigan.

Author Manuscript

This article is protected by copyright. All rights reserved.

REFERENCES

1. Park MH, Falconer C, Viner RM, Kinra S. The impact of childhood obesity on morbidity and mortality in adulthood: a systematic review. *Obes Rev.* 2012;13(11):985-1000.
2. (NCD-RisC) NRFC. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet.* 2017;390(10113):2627-2642.
3. Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. *Obes Rev.* 2009;10(6):648-659.
4. Leikin-Frenkel A, Shomonov-Wagner L, Juknat A, Pasmanik-Chor M. Maternal Diet Enriched with alpha-Linolenic or Saturated Fatty Acids Differentially Regulates Gene Expression in the Liver of Mouse Offspring. *J Nutrigenet Nutrigenomics.* 2015;8(4-6):185-194.
5. Muhlhausler BS, Ailhaud GP. Omega-6 polyunsaturated fatty acids and the early origins of obesity. *Curr Opin Endocrinol Diabetes Obes.* 2013;20(1):56-61.
6. Martinez-Victoria E, Yago MD. Omega 3 polyunsaturated fatty acids and body weight. *Br J Nutr.* 2012;107 Suppl 2:S107-116.
7. Naughton SS, Mathai ML, Hryciw DH, McAinch AJ. Linoleic acid and the pathogenesis of obesity. *Prostaglandins Other Lipid Mediat.* 2016;125:90-99.
8. Hooper L, Al-Khudairy L, Abdelhamid AS, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev.* 2018;11:Cd011094.

Author Manuscript

This article is protected by copyright. All rights reserved.

9. Shils ME, Shike M. *Modern Nutrition in Health and Disease.* Lippincott Williams & Wilkins; 2006.

10. Carlson SE, Colombo J. Docosahexaenoic Acid and Arachidonic Acid Nutrition in Early Development. *Adv Pediatr.* 2016;63(1):453-471.

11. Kinra S, Rameshwar Sarma KV, Ghafoorunissa, et al. Effect of integration of supplemental nutrition with public health programmes in pregnancy and early childhood on cardiovascular risk in rural Indian adolescents: long term follow-up of Hyderabad nutrition trial. *Bmj.* 2008;337:a605.

12. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. *Nature.* 2008;453(7196):783-787.

13. Voortman T, van den Hooven EH, Braun KV, et al. Effects of polyunsaturated fatty acid intake and status during pregnancy, lactation, and early childhood on cardiometabolic health: A systematic review. *Prog Lipid Res.* 2015;59:67-87.

14. Stein AD, Wang M, Martorell R, et al. Growth to age 18 months following prenatal supplementation with docosahexaenoic acid differs by maternal gravidity in Mexico. *J Nutr.* 2011;141(2):316-320.

15. Tinoco SM, Sichieri R, Setta CL, Moura AS, Carmo MG. n-3 polyunsaturated fatty acids in milk is associate to weight gain and growth in premature infants. *Lipids Health Dis.* 2009;8:23.

16. van der Merwe LF, Moore SE, Fulford AJ, et al. Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development. *Am J Clin Nutr.* 2013;97(1):45-57.

Author Manuscript

This article is protected by copyright. All rights reserved.

17. Petrova S, Dimitrov P, Willett WC, Campos H. The global availability of n-3 fatty acids. *Public Health Nutr.* 2011;14(7):1157-1164.

18. Lozoff B, De Andraca I, Castillo M, Smith JB, Walter T, Pino P. Behavioral and developmental effects of preventing iron-deficiency anemia in healthy full-term infants. *Pediatrics.* 2003;112(4):846-854.

19. Roncagliolo M, Garrido M, Walter T, Peirano P, Lozoff B. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. *Am J Clin Nutr.* 1998;68(3):683-690.

20. Burrows R, Correa-Burrows P, Reyes M, Blanco E, Albala C, Gahagan S. High cardiometabolic risk in healthy Chilean adolescents: associations with anthropometric, biological and lifestyle factors. *Public Health Nutr.* 2016;19(3):486-493.

21. Matthan NR, Ip B, Resteghini N, Ausman LM, Lichtenstein AH. Long-term fatty acid stability in human serum cholesteryl ester, triglyceride, and phospholipid fractions. *J Lipid Res.* 2010;51(9):2826-2832.

22. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol.* 1959;37(8):911-917.

23. Morrison WR, Smith LM. PREPARATION OF FATTY ACID METHYL ESTERS AND DIMETHYLACETALS FROM LIPIDS WITH BORON FLUORIDE--METHANOL. *J Lipid Res.* 1964;5:600-608.

24. Rudolph MC, Jackman MR, Presby DM, et al. Low Neonatal Plasma n-6/n-3 PUFA Ratios Regulate Offspring Adipogenic Potential and Condition Adult Obesity Resistance. *Diabetes.* 2018;67(4):651-661.

Author Manuscript

This article is protected by copyright. All rights reserved.

25. de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. *Bull World Health Organ.* 2007;85(9):660-667.

26. Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet.* 2014;384(9946):857-868.

27. Alvarez ML, Muzzo S, Ivanovic D. [Scale for measurement of socioeconomic level, in the health area]. *Rev Med Chil.* 1985;113(3):243-249.

28. Thompson AK, Minihane AM, Williams CM. Trans fatty acids and weight gain. *Int J Obes (Lond).* 2011;35(3):315-324.

29. Perng W, Mora-Plazas M, Marin C, Villamor E. Iron status and linear growth: a prospective study in school-age children. *Eur J Clin Nutr.* 2013;67(6):646-651.

30. Durrleman S, Simon R. Flexible regression models with cubic splines. *Stat Med.* 1989;8(5):551-561.

31. Baylin A, Mora-Plazas M, Cobos-de Rangel O, Lopez-Arana S, Campos H, Villamor E. Predictors of usage and fatty acid composition of cooking fats in Bogota, Colombia. *Public Health Nutr.* 2009;12(4):531-537.

32. White H. A Heteroskedasticity-Consistent Covariance-Matrix Estimator and a Direct Test for Heteroskedasticity. *Econometrica.* 1980;48(4):817-838.

33. Vidakovic AJ, Gishti O, Voortman T, et al. Maternal plasma PUFA concentrations during pregnancy and childhood adiposity: the Generation R Study. *Am J Clin Nutr.* 2016;103(4):1017-1025.

Author Manuscript

This article is protected by copyright. All rights reserved.

34. Donahue SM, Rifas-Shiman SL, Gold DR, Jouni ZE, Gillman MW, Oken E. Prenatal fatty acid status and child adiposity at age 3 y: results from a US pregnancy cohort. *Am J Clin Nutr.* 2011;93(4):780-788.

35. Helland IB, Smith L, Blomen B, Saarem K, Saugstad OD, Drevon CA. Effect of supplementing pregnant and lactating mothers with n-3 very-long-chain fatty acids on children's IQ and body mass index at 7 years of age. *Pediatrics.* 2008;122(2):e472-479.

36. Scholtens S, Wijga AH, Smit HA, et al. Long-chain polyunsaturated fatty acids in breast milk and early weight gain in breast-fed infants. *Br J Nutr.* 2009;101(1):116-121.

37. Wolff R. *trans*-Polyunsaturated fatty acids in French edible rapeseed and soybean oils. *Journal of the American Oil Chemists' Society.* 1992;69(2):106-110.

38. Colon-Ramos U, Monge-Rojas R, Campos H. Impact of WHO recommendations to eliminate industrial trans-fatty acids from the food supply in Latin America and the Caribbean. *Health Policy Plan.* 2014;29(5):529-541.

39. Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. *Nat Rev Endocrinol.* 2009;5(6):335-344.

40. See VHL, Mori TA, Prescott SL, Beilin LJ, Burrows S, Huang RC. Cardiometabolic Risk Factors at 5 Years After Omega-3 Fatty Acid Supplementation in Infancy. *Pediatrics.* 2018;142(1).

41. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet.* 2010;375(9710):181-183.

42. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. *Eur Heart J.* 2007;28(7):850-856.

Author Manuscript

This article is protected by copyright. All rights reserved.

43. Stratakis N, Gielen M, Margetaki K, et al. Polyunsaturated fatty acid status at birth, childhood growth, and cardiometabolic risk: a pooled analysis of the MEFAB and RHEA cohorts. *Eur J Clin Nutr.* 2019;73(4):566-576.

44. Kaur G, Guo XF, Sinclair AJ. Short update on docosapentaenoic acid: a bioactive long-chain n-3 fatty acid. *Curr Opin Clin Nutr Metab Care.* 2016;19(2):88-91.

45. Ghasemi Fard S, Linderborg KM, Turchini GM, Sinclair AJ. Comparison of the bioavailability of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in the rat. *Prostaglandins Leukot Essent Fatty Acids.* 2014;90(1):23-26.

46. Rump P, Popp-Snijders C, Heine RJ, Hornstra G. Components of the insulin resistance syndrome in seven-year-old children: relations with birth weight and the polyunsaturated fatty acid content of umbilical cord plasma phospholipids. *Diabetologia.* 2002;45(3):349-355.

47. Kennedy K, Ross S, Isaacs EB, et al. The 10-year follow-up of a randomised trial of long-chain polyunsaturated fatty acid supplementation in preterm infants: effects on growth and blood pressure. *Arch Dis Child.* 2010;95(8):588-595.

48. Murff HJ, Edwards TL. Endogenous Production of Long-Chain Polyunsaturated Fatty Acids and Metabolic Disease Risk. *Curr Cardiovasc Risk Rep.* 2014;8(12).

49. Wolters M, Schlenz H, Bornhorst C, et al. Desaturase Activity Is Associated With Weight Status and Metabolic Risk Markers in Young Children. *J Clin Endocrinol Metab.* 2015;100(10):3760-3769.

50. Abe Y, Okada T, Iguchi H, et al. Association of changes in body fatness and fatty acid composition of plasma phospholipids during early puberty in Japanese children. *J Atheroscler Thromb.* 2012;19(12):1102-1109.

This article is protected by copyright. All rights reserved.

Author Manuscript

51. Tosi F, Sartori F, Guarini P, Olivieri O, Martinelli N. Delta-5 and delta-6 desaturases: crucial enzymes in polyunsaturated fatty acid-related pathways with pleiotropic influences in health and disease. *Adv Exp Med Biol.* 2014;824:61-81.

52. Helba M, Binkovitz LA. Pediatric body composition analysis with dual-energy X-ray absorptiometry. *Pediatr Radiol.* 2009;39(7):647-656.

53. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res.* 2008;47(5):348-380.

54. Ripka WL, Orsso CE, Haqq AM, Luz TG, Prado CM, Ulbricht L. Lean mass reference curves in adolescents using dual-energy x-ray absorptiometry (DXA). *PLoS One.* 2020;15(2):e0228646.

55. Glymour MM, Weuve J, Berkman LF, Kawachi I, Robins JM. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. *Am J Epidemiol.* 2005;162(3):267-278.

56. Olivares S, Kain J, Lera L, Pizarro F, Vio F, Moron C. Nutritional status, food consumption and physical activity among Chilean school children: a descriptive study. *Eur J Clin Nutr.* 2004;58(9):1278-1285.

57. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Chile: determinants and consequences. *Public Health Nutr.* 2002;5(1a):123-128.

58. Atalah E, Amigo H, Bustos P. Does Chile's nutritional situation constitute a double burden? *Am J Clin Nutr.* 2014;100(6):1623s-1627s.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 1. Changes in BMI-for-age Z scores (BMIZ)[a] from 1 to 16 years of age by serum n-3 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	1 y BMIZ (mean ± SE)[b]	16 y BMIZ (mean ± SE)	Change in BMIZ 1 - 16 y (mean ± SE)[b]	Adjusted difference in change (95% CI)[c]
Overall	636	0.81 ± 0.04	0.72 ± 0.05	-0.09 ± 0.05	
N-3					
ALA (18:3 n-3)					
Q1 (0.21)	159	0.81 ± 0.07	0.68 ± 0.09	-0.13 ± 0.11	Reference
Q2 (0.28)	159	0.73 ± 0.07	0.61 ± 0.09	-0.12 ± 0.10	-0.01 (-0.30, 0.27)
Q3 (0.39)	159	0.88 ± 0.08	0.76 ± 0.09	-0.12 ± 0.10	-0.04 (-0.33, 0.25)
Q4 (1.32)	159	0.84 ± 0.08	0.83 ± 0.09	-0.01 ± 0.10	0.06 (-0.24, 0.36)
P, trend[d]				0.33	0.55
EPA (20:5 n-3)					
Q1 (0.07)	159	0.78 ± 0.07	0.65 ± 0.09	-0.12 ± 0.10	Reference
Q2 (0.13)	159	0.80 ± 0.07	0.80 ± 0.09	0.00 ± 0.10	0.10 (-0.18, 0.38)
Q3 (0.22)	159	0.81 ± 0.07	0.77 ± 0.09	-0.05 ± 0.10	0.07 (-0.21, 0.35)
Q4 (0.34)	159	0.86 ± 0.08	0.66 ± 0.09	-0.20 ± 0.11	-0.06 (-0.35, 0.23)
P, trend				0.46	0.56
DPA (22:5 n-3)					
Q1 (0.08)	160	0.78 ± 0.07	0.48 ± 0.09	-0.30 ± 0.09	Reference
Q2 (0.11)	158	0.78 ± 0.07	0.72 ± 0.09	-0.05 ± 0.10	0.23 (-0.04, 0.50)
Q3 (0.14)	159	0.75 ± 0.07	0.98 ± 0.09	0.23 ± 0.10	0.54 (0.26, 0.82)
Q4 (0.21)	159	0.94 ± 0.08	0.71 ± 0.09	-0.24 ± 0.11	0.07 (-0.21, 0.35)
P, trend				0.75	0.71
DHA (22:6 n-3)					
Q1 (0.23)	158	0.84 ± 0.08	0.67 ± 0.10	-0.17 ± 0.10	Reference
Q2 (0.43)	160	0.87 ± 0.06	0.69 ± 0.09	-0.17 ± 0.10	0.05 (-0.23, 0.33)
Q3 (0.62)	159	0.71 ± 0.07	0.72 ± 0.09	0.01 ± 0.10	0.20 (-0.11, 0.50)
Q4 (0.90)	159	0.83 ± 0.08	0.80 ± 0.09	-0.03 ± 0.10	0.17 (-0.16, 0.50)
P, trend				0.19	0.28

Author Manuscript

This article is protected by copyright. All rights reserved.

Footnotes to Table 1

[a] According to the World Health Organization Growth Reference for children ages 5-19 y.[25]

[b] From growth curves estimated using mixed effects linear regression models with BMIZ as the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age slopes to account for within-child correlations of repeated BMI measurements.

[c] Adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), and total serum trans fatty acids (FA). All n-3 PUFA are adjusted for LA and total long-chain n-6 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate FA are represented with linear and restricted cubic spline terms.

[d] From mixed effects linear regression models with BMI as the outcome and a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 2. Body composition[a] at 16 y of age by serum n-3 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	Total fat mass (kg)		Truncal fat mass (kg)		Total lean mass (kg)		% Total fat mass		% Truncal fat mass	
		Mean ± SD	Adjusted difference (95% CI)[b]	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)
Overall	382	19.8 ± 10.1		10.0 ± 5.7		44.0 ± 8.9		29.1 ± 10.9		49.3 ± 5.9	
ALA (18:3 n-3)											
Q1 (0.21)	98	19.5 ± 9.9	Reference	9.8 ± 5.8	Reference	42.8 ± 8.5	Reference	29.4 ± 11.1	Reference	48.7 ± 6.3	Reference
Q2 (0.28)	98	18.4 ± 8.9	-0.4 (-2.7, 2.0)	9.0 ± 4.9	-0.5 (-1.9, 0.9)	43.8 ± 8.4	-0.1 (-1.6, 1.3)	27.8 ± 9.8	-0.2 (-2.3, 1.9)	47.6 ± 5.3	-1.1 (-2.8, 0.5)
Q3 (0.39)	90	19.6 ± 9.3	0.4 (-2.2, 2.9)	9.8 ± 5.3	0.1 (-1.4, 1.6)	45.0 ± 9.8	1.1 (-0.5, 2.7)	28.6 ± 10.2	0.1 (-2.2, 2.4)	49.0 ± 5.9	0.1 (-1.7, 1.9)
Q4 (1.32)	96	21.8 ± 12.0	1.9 (-1.0, 4.7)	11.5 ± 6.5	1.3 (-0.3, 2.9)	44.3 ± 8.8	0.6 (-1.0, 2.2)	30.5 ± 12.3	1.1 (-1.4, 3.5)	51.9 ± 5.0	2.9 (1.2, 4.7)
P, trend[c]		0.05	0.12	0.008	0.03	0.47	0.55	0.21	0.28	<0.0001	<0.0001
EPA (20:5 n-3)											
Q1 (0.07)	95	19.3 ± 11.2	Reference	9.9 ± 6.1	Reference	43.0 ± 8.6	Reference	28.6 ± 11.7	Reference	50.3 ± 5.5	Reference
Q2 (0.13)	95	20.5 ± 9.3	1.1 (-1.4, 3.7)	10.2 ± 5.1	0.1 (-1.3, 1.5)	43.4 ± 8.8	-0.9 (-2.4, 0.6)	30.3 ± 10.0	2.2 (0.1, 4.4)	48.6 ± 5.8	-2.4 (-3.9, -0.8)
Q3 (0.22)	99	19.6 ± 10.3	0.5 (-2.3, 3.3)	10.0 ± 5.9	0.1 (-1.5, 1.7)	45.0 ± 9.4	0.6 (-1.0, 2.2)	28.5 ± 11.2	0.8 (-1.6, 3.2)	49.7 ± 5.7	-1.6 (-3.2, 0.0)
Q4 (0.34)	93	19.8 ± 9.8	-0.1 (-2.7, 2.6)	9.9 ± 5.7	-0.3 (-1.8, 1.2)	44.4 ± 8.7	0.1 (-1.5, 1.6)	28.9 ± 10.7	0.2 (-2.1, 2.5)	48.6 ± 6.3	-2.5 (-4.2, -0.7)
P, trend		0.98	0.74	0.95	0.64	0.19	0.42	0.79	0.62	0.17	0.04
DPA (22:5 n-3)											
Q1 (0.08)	91	17.1 ± 9.0	Reference	8.5 ± 5.1	Reference	43.5 ± 9.0	Reference	26.7 ± 10.7	Reference	48.1 ± 5.9	Reference
Q2 (0.11)	96	20.1 ± 9.8	1.8 (-0.6, 4.2)	10.2 ± 5.5	1.1 (-0.3, 2.5)	42.8 ± 8.5	0.6 (-1.0, 2.1)	30.0 ± 11.0	1.6 (-0.6, 3.8)	49.5 ± 5.5	1.6 (-0.1, 3.3)
Q3 (0.14)	98	21.2 ± 10.7	4.1 (1.4, 6.8)	10.9 ± 6.0	2.4 (0.9, 4.0)	45.7 ± 9.5	1.6 (-0.1, 3.3)	29.7 ± 10.7	3.5 (1.1, 5.9)	50.3 ± 5.7	2.6 (0.8, 4.3)
Q4 (0.21)	97	20.6 ± 10.6	2.3 (-0.2, 4.8)	10.4 ± 5.8	1.3 (-0.2, 2.7)	43.8 ± 8.3	0.9 (-0.8, 2.5)	29.9 ± 11.0	1.8 (-0.5, 4.1)	49.2 ± 6.1	1.1 (-0.6, 2.9)
P, trend		0.04	0.10	0.04	0.13	0.48	0.29	0.10	0.15	0.30	0.33

Author Manuscript

This article is protected by copyright. All rights reserved.

DHA (22:6 n-3)												
Q1 (0.23)	92	19.1 ± 10.5	Reference	9.7 ± 6.0	Reference	45.3 ± 8.8	Reference	27.7 ± 11.6	Reference	49.2 ± 6.3	Reference	
Q2 (0.43)	100	19.7 ± 9.5	1.1 (-1.6, 3.7)	10.2 ± 5.4	0.7 (-0.8, 2.3)	43.3 ± 8.5	-1.5 (-3.0, 0.0)	29.3 ± 10.7	2.1 (-0.3, 4.6)	50.8 ± 5.3	1.5 (-0.1, 3.1)	
Q3 (0.62)	95	20.0 ± 10.6	0.1 (-3.0, 3.2)	10.0 ± 5.9	-0.2 (-2.0, 1.5)	43.7 ± 8.7	0.1 (-1.5, 1.8)	29.4 ± 10.8	0.0 (-2.8, 2.8)	48.8 ± 6.2	-1.1 (-3.1, 0.9)	
Q4 (0.90)	95	20.3 ± 10.1	-0.4 (-3.9, 3.2)	10.1 ± 5.5	-0.6 (-2.6, 1.4)	43.6 ± 9.5	-1.0 (-2.8, 0.9)	29.9 ± 10.5	0.2 (-2.8, 3.3)	48.3 ± 5.4	-1.8 (-3.9, 0.3)	
P, trend		0.42	0.72	0.77	0.42	0.31	0.54	0.19	0.84	0.06	0.03	

Author Manuscript

This article is protected by copyright. All rights reserved.

Footnotes to Table 2

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-3 PUFA are adjusted for LA and total long-chain n-6 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 3. Changes in BMI-for-age Z scores (BMIZ)[a] from 1 to 16 years of age by serum n-6 polyunsaturated fatty acid biomarkers and desaturase activity indices at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	1 y BMIZ (mean ± SE)[b]	16 y BMIZ (mean ± SE)	Change in BMIZ 1 - 16 y (mean ± SE)[b]	Adjusted difference in change (95% CI)[c]
LA (18:2 n-6)					
Q1 (16.53)	159	0.78 ± 0.07	0.56 ± 0.10	-0.23 ± 0.11	Reference
Q2 (21.31)	159	0.72 ± 0.08	0.79 ± 0.09	0.07 ± 0.10	0.34 (0.03, 0.64)
Q3 (25.87)	159	0.80 ± 0.07	0.74 ± 0.09	-0.06 ± 0.09	0.22 (-0.11, 0.54)
Q4 (30.97)	159	0.95 ± 0.08	0.80 ± 0.09	-0.16 ± 0.10	0.11 (-0.27, 0.49)
P, trend[d]				0.88	0.73
GLA (18:3 n-6)					
Q1 (0.00)	159	0.83 ± 0.07	0.64 ± 0.09	-0.18 ± 0.10	Reference
Q2 (0.07)	159	0.87 ± 0.07	0.79 ± 0.09	-0.07 ± 0.10	0.10 (-0.18, 0.37)
Q3 (0.11)	159	0.81 ± 0.08	0.69 ± 0.10	-0.12 ± 0.11	0.05 (-0.25, 0.35)
Q4 (0.42)	159	0.75 ± 0.08	0.75 ± 0.09	0.00 ± 0.09	0.21 (-0.08, 0.49)
P, trend				0.21	0.18
DGLA (20:3 n-6)					
Q1 (0.44)	159	0.84 ± 0.08	0.68 ± 0.09	-0.16 ± 0.10	Reference
Q2 (0.61)	159	0.74 ± 0.07	0.84 ± 0.09	0.10 ± 0.10	0.25 (-0.03, 0.53)
Q3 (0.76)	159	0.76 ± 0.07	0.73 ± 0.09	-0.03 ± 0.10	0.13 (-0.15, 0.40)
Q4 (0.96)	159	0.90 ± 0.08	0.63 ± 0.10	-0.27 ± 0.11	-0.12 (-0.41, 0.17)
P, trend				0.29	0.28
AA (20:4 n-6)					
Q1 (0.94)	159	0.90 ± 0.07	0.66 ± 0.09	-0.24 ± 0.10	Reference
Q2 (1.31)	159	0.68 ± 0.07	0.68 ± 0.09	0.00 ± 0.10	0.26 (-0.04, 0.56)
Q3 (1.65)	159	0.78 ± 0.07	0.68 ± 0.09	-0.09 ± 0.10	0.22 (-0.10, 0.55)
Q4 (2.27)	159	0.90 ± 0.08	0.86 ± 0.10	-0.04 ± 0.11	0.32 (-0.04, 0.68)
P, trend				0.29	0.13
N-6:N-3 ratio					
Q1 (12.7:1)	159	0.88 ± 0.08	0.78 ± 0.09	-0.10 ± 0.11	Reference
Q2 (18.3:1)	159	0.71 ± 0.08	0.66 ± 0.09	-0.04 ± 0.10	0.06 (-0.22, 0.35)
Q3 (22.9:1)	159	0.81 ± 0.07	0.74 ± 0.10	-0.07 ± 0.10	0.06 (-0.23, 0.35)
Q4 (32.0:1)	159	0.85 ± 0.07	0.70 ± 0.09	-0.15 ± 0.09	0.00 (-0.28, 0.29)
P, trend				0.63	0.96

Author Manuscript

This article is protected by copyright. All rights reserved.

Desaturase activity indices					
Δ6-Desaturase index (GLA/LA)					
Q1 (0.000)	159	0.85 ± 0.08	0.63 ± 0.08	-0.22 ± 0.10	Reference
Q2 (0.003)	159	0.81 ± 0.07	0.84 ± 0.10	0.03 ± 0.11	0.22 (-0.06, 0.50)
Q3 (0.005)	159	0.85 ± 0.07	0.66 ± 0.09	-0.19 ± 0.11	0.02 (-0.27, 0.31)
Q4 (0.017)	159	0.74 ± 0.08	0.76 ± 0.09	0.01 ± 0.09	0.24 (-0.04, 0.52)
P, trend				0.19	0.18
Δ5-Desaturase index (AA/DGLA)					
Q1 (1.57)	159	0.83 ± 0.07	0.63 ± 0.09	-0.20 ± 0.10	Reference
Q2 (1.94)	159	0.76 ± 0.07	0.66 ± 0.09	-0.10 ± 0.10	0.05 (-0.22, 0.33)
Q3 (2.42)	159	0.84 ± 0.07	0.88 ± 0.09	0.04 ± 0.11	0.13 (-0.17, 0.43)
Q4 (3.21)	159	0.83 ± 0.08	0.71 ± 0.09	-0.11 ± 0.10	0.01 (-0.31, 0.32)
P, trend				0.54	0.99

Author Manuscript

This article is protected by copyright. All rights reserved.

Footnotes to Table 3

[a] According to the World Health Organization Growth Reference for children ages 5-19 y.[25]

[b] From growth curves estimated using mixed effects linear regression models with BMI as the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age slopes to account for within-child correlations of repeated BMI measurements.

[c] Adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥ 6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), and total serum trans fatty acids. All n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[d] From mixed effects linear regression models with BMI as the outcome and a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table 4. Body composition[a] at 16 y of age by serum n-6 polyunsaturated fatty acid biomarkers and desaturase activity indices at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	N	Total fat mass (kg)		Truncal fat mass (kg)		Total lean mass (kg)		% Total fat mass		% Truncal fat mass	
		Mean ± SD	Adjusted difference (95% CI)[b]	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)	Mean ± SD	Adjusted difference (95% CI)
LA (18:2 n-6)											
Q1 (16.53)	98	19.0 ± 11.3	Reference	9.5 ± 6.1	Reference	43.0 ± 8.4	Reference	28.3 ± 12.1	Reference	49.0 ± 5.8	Reference
Q2 (21.31)	95	20.3 ± 9.2	1.4 (-1.3, 4.1)	10.4 ± 5.4	0.9 (-0.6, 2.5)	43.9 ± 9.0	0.2 (-1.5, 1.9)	29.9 ± 9.7	1.9 (-0.5, 4.2)	49.6 ± 6.1	0.9 (-0.8, 2.6)
Q3 (25.87)	89	19.6 ± 9.8	1.1 (-1.7, 4.0)	9.9 ± 5.5	0.8 (-0.8, 2.3)	45.6 ± 9.0	1.1 (-0.6, 2.8)	28.4 ± 10.8	1.3 (-1.2, 3.8)	49.5 ± 5.8	1.3 (-0.4, 3.1)
Q4 (30.97)	100	20.2 ± 10.2	0.7 (-2.7, 4.1)	10.2 ± 5.7	0.6 (-1.3, 2.5)	43.5 ± 9.0	0.1 (-1.9, 2.1)	29.7 ± 10.8	1.1 (-1.8, 3.9)	49.1 ± 5.8	0.9 (-1.0, 2.9)
P, trend[c]		0.52	0.74	0.54	0.61	0.47	0.73	0.57	0.56	>0.99	0.31
GLA (18:3 n-6)											
Q1 (0.00)	86	18.2 ± 9.0	Reference	9.2 ± 5.1	Reference	44.4 ± 9.2	Reference	27.5 ± 10.5	Reference	49.3 ± 5.9	Reference
Q2 (0.07)	89	19.7 ± 11.1	0.9 (-1.7, 3.5)	10.1 ± 6.2	0.6 (-0.9, 2.0)	44.7 ± 8.7	0.1 (-1.5, 1.7)	28.3 ± 11.8	0.6 (-1.8, 2.9)	50.2 ± 5.7	0.6 (-1.1, 2.3)
Q3 (0.11)	96	20.3 ± 11.0	1.2 (-1.5, 3.8)	10.2 ± 6.1	0.5 (-1.0, 2.1)	43.7 ± 9.3	0.4 (-1.3, 2.1)	29.6 ± 11.3	0.9 (-1.5, 3.3)	49.0 ± 6.4	-0.6 (-2.3, 1.2)
Q4 (0.42)	111	20.7 ± 9.4	2.8 (0.4, 5.2)	10.4 ± 5.3	1.5 (0.2, 2.9)	43.3 ± 8.5	-0.3 (-1.8, 1.3)	30.5 ± 9.9	2.9 (0.7, 5.1)	48.8 ± 5.4	0.7 (-1.0, 2.3)
P, trend		0.13	0.03	0.25	0.03	0.28	0.58	0.04	0.005	0.30	0.38
DGLA (20:3 n-6)											
Q1 (0.44)	89	19.5 ± 10.2	Reference	9.8 ± 5.6	Reference	43.0 ± 9.2	Reference	29.2 ± 11.3	Reference	49.1 ± 5.8	Reference
Q2 (0.61)	98	20.6 ± 9.6	2.0 (-0.7, 4.6)	10.6 ± 5.6	1.3 (-0.2, 2.8)	44.7 ± 8.5	0.8 (-0.6, 2.3)	29.6 ± 10.3	1.9 (-0.4, 4.2)	50.1 ± 5.5	1.3 (-0.3, 2.9)
Q3 (0.76)	94	19.3 ± 10.1	0.5 (-2.0, 3.1)	9.7 ± 5.4	0.4 (-1.0, 1.9)	44.1 ± 8.9	1.1 (-0.5, 2.6)	28.6 ± 10.8	0.4 (-1.8, 2.7)	49.6 ± 5.4	1.3 (-0.4, 2.9)
Q4 (0.96)	101	19.8 ± 10.7	0.6 (-2.2, 3.4)	9.9 ± 6.1	0.4 (-1.2, 1.9)	44.0 ± 9.0	0.5 (-1.2, 2.3)	28.9 ± 11.3	0.3 (-2.1, 2.8)	48.4 ± 6.5	0.1 (-1.7, 1.9)
P, trend		0.97	0.99	0.82	0.98	0.63	0.58	0.73	0.83	0.32	0.89

Author Manuscript

This article is protected by copyright. All rights reserved.

AA (20:4 n-6)											
Q1 (0.94)	87	19.5 ± 9.8	Reference	10.0 ± 5.6	Reference	42.6 ± 8.2	Reference	29.4 ± 10.9	Reference	49.9 ± 5.2	Reference
Q2 (1.31)	107	19.3 ± 9.3	0.2 (-2.6, 3.0)	9.8 ± 5.4	0.1 (-1.5, 1.7)	44.1 ± 9.4	1.3 (-0.4, 2.9)	28.7 ± 10.0	-0.1 (-2.5, 2.4)	49.7 ± 5.8	-0.2 (-1.9, 1.5)
Q3 (1.65)	98	19.0 ± 10.6	-0.2 (-3.3, 2.9)	9.6 ± 5.8	-0.3 (-2.0, 1.5)	44.3 ± 8.8	1.2 (-0.6, 2.9)	28.0 ± 11.8	-0.7 (-3.3, 1.9)	49.0 ± 6.3	-1.0 (-2.8, 0.8)
Q4 (2.27)	90	21.5 ± 10.8	1.1 (-2.7, 5.0)	10.7 ± 6.0	0.4 (-1.6, 2.5)	44.7 ± 8.9	0.2 (-1.9, 2.3)	30.4 ± 10.9	1.6 (-1.5, 4.7)	48.6 ± 6.0	-1.1 (-3.2, 1.0)
P, trend		0.18	0.57	0.37	0.72	0.12	0.87	0.47	0.31	0.09	0.23
N-6:N-3 ratio											
Q1 (12.7:1)	91	20.8 ± 10.9	Reference	10.9 ± 6.1	Reference	43.5 ± 8.6	Reference	30.1 ± 11.4	Reference	51.4 ± 5.5	Reference
Q2 (18.3:1)	98	18.6 ± 9.5	-0.9 (-3.4, 1.7)	9.2 ± 5.2	-1.0 (-2.5, 0.4)	44.5 ± 8.4	-0.1 (-1.6, 1.3)	27.8 ± 10.5	-0.3 (-2.5, 1.8)	47.8 ± 5.5	-3.4 (-5.0, -1.8)
Q3 (22.9:1)	94	20.6 ± 10.6	0.6 (-2.2, 3.4)	10.4 ± 5.9	0.0 (-1.7, 1.6)	44.9 ± 10.2	1.5 (-0.1, 3.0)	29.5 ± 10.8	0.1 (-2.2, 2.5)	49.2 ± 5.8	-2.1 (-3.7, -0.4)
Q4 (32.0:1)	99	19.3 ± 9.5	-0.1 (-2.6, 2.5)	9.7 ± 5.4	-0.3 (-1.8, 1.2)	42.9 ± 8.2	-0.9 (-2.5, 0.7)	29.1 ± 10.9	0.6 (-1.7, 2.9)	49.0 ± 6.0	-1.8 (-3.4, -0.2)
P, trend		0.52	0.81	0.38	>0.99	0.46	0.40	0.85	0.51	0.06	0.20
Desaturase activity indices											
Δ6-Desaturase index (GLA/LA)											
Q1 (0.000)	92	18.2 ± 8.8	Reference	9.2 ± 5.0	Reference	44.0 ± 9.3	Reference	27.7 ± 10.3	Reference	49.5 ± 5.8	Reference
Q2 (0.003)	82	20.6 ± 11.2	1.2 (-1.4, 3.9)	10.5 ± 6.2	0.7 (-0.8, 2.2)	44.7 ± 9.2	0.2 (-1.4, 1.8)	29.4 ± 11.7	1.1 (-1.3, 3.5)	49.8 ± 5.9	0.1 (-1.6, 1.8)
Q3 (0.005)	96	19.0 ± 10.9	0.8 (-1.8, 3.4)	9.5 ± 5.9	0.3 (-1.2, 1.8)	44.5 ± 8.5	0.3 (-1.2, 1.8)	27.8 ± 11.5	0.4 (-1.9, 2.8)	48.7 ± 6.4	-0.9 (-2.6, 0.9)
Q4 (0.017)	112	21.2 ± 9.6	3.1 (0.7, 5.5)	10.7 ± 5.5	1.7 (0.3, 3.1)	42.8 ± 8.6	-0.2 (-1.8, 1.4)	31.2 ± 10.0	3.1 (1.0, 5.3)	49.2 ± 5.4	0.7 (-0.8, 2.3)
P, trend		0.06	0.01	0.10	0.02	0.16	0.64	0.01	0.003	0.71	0.23
Δ5-Desaturase index (AA/DGLA)											
Q1 (1.57)	102	19.0 ± 10.1	Reference	9.7 ± 5.7	Reference	43.9 ± 8.3	Reference	28.1 ± 10.9	Reference	49.9 ± 5.5	Reference
Q2 (1.94)	97	18.9 ± 9.0	-0.6 (-3.1, 1.8)	9.6 ± 5.3	-0.5 (-1.9, 1.0)	44.0 ± 9.5	0.5 (-1.1, 2.0)	28.4 ± 10.5	-0.4 (-2.7, 1.9)	49.3 ± 6.2	-1.2 (-2.8, 0.4)
Q3 (2.42)	96	21.4 ± 11.0	0.4 (-2.3, 3.1)	10.9 ± 6.1	0.2 (-1.4, 1.7)	44.0 ± 9.4	0.3 (-1.3, 1.9)	30.7 ± 11.3	0.3 (-2.1, 2.7)	49.4 ± 5.8	-1.0 (-2.7, 0.7)
Q4 (3.21)	87	19.9 ± 10.3	-0.7 (-3.8, 2.4)	9.8 ± 5.6	-0.6 (-2.4, 1.1)	43.8 ± 8.4	-0.6 (-2.3, 1.1)	29.2 ± 10.7	-0.3 (-2.9, 2.4)	48.4 ± 5.8	-1.9 (-3.8, -0.1)
P, trend		0.35	0.78	0.61	0.57	0.93	0.38	0.32	0.93	0.08	0.07

Author Manuscript

This article is protected by copyright. All rights reserved.

Footnotes to Table 4

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as continuous.

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

Serum polyunsaturated fatty acids in infancy are associated with body composition in adolescence:

Supporting information

Kerry Flannagan[1], Sheila Gahagan[2], Arun Das[3],

Raquel Burrows[4], Betsy Lozoff[5], and Eduardo Villamor[1]

[1]Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; [2]Division of Child Development and Community Health, University of California, San Diego, CA, USA; [3]Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA; [4]Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile; [5]Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI, USA.

This article is protected by copyright. All rights reserved.

Author Manuscript



Figure S1. Flowchart of sample sizes at each inclusion step into cohort of children from Santiago, Chile

This article is protected by copyright. All rights reserved.

Table S1. Cross-sectional unadjusted analyses of serum n-3 polyunsaturated fatty acids biomarkers[a] by categories of sociodemographic and other characteristics among infants from Santiago, Chile

Characteristics	N	ALA 18:3(n-3)	EPA 20:5(n-3)	DPA 22:5(n-3)	DHA 22:6(n-3)
Overall	636	0.66 ± 1.05	0.19 ± 0.12	0.14 ± 0.08	0.58 ± 0.34
Sociodemographic characteristics					
Sex					
Female	296	0.69 ± 1.21	0.18 ± 0.12	0.14 ± 0.08	0.61 ± 0.37
Male	340	0.63 ± 0.89	0.20 ± 0.12	0.14 ± 0.08	0.55 ± 0.30
P[b]		0.44	0.11	0.93	0.02
Birth length					
Average for gestational age[c]	425	0.65 ± 1.14	0.19 ± 0.11	0.14 ± 0.09	0.57 ± 0.34
Large for gestational age	211	0.68 ± 0.84	0.20 ± 0.13	0.14 ± 0.07	0.59 ± 0.32
P[b]		0.73	0.10	0.97	0.61
Birth weight					
Average for gestational age	467	0.66 ± 1.15	0.19 ± 0.12	0.14 ± 0.09	0.57 ± 0.33
Large for gestational age	169	0.66 ± 0.72	0.20 ± 0.13	0.14 ± 0.06	0.60 ± 0.36
P[b]		0.99	0.18	0.88	0.31
Breastfeeding					
Breastfeeding <6 mo	206	0.76 ± 0.95	0.18 ± 0.11	0.14 ± 0.08	0.52 ± 0.32
Mixed bottle/breastfeeding, ≥6 mo	231	0.65 ± 1.36	0.19 ± 0.11	0.14 ± 0.09	0.57 ± 0.33
Exclusive breastfeeding, ≥6 mo	189	0.58 ± 0.68	0.22 ± 0.13	0.14 ± 0.07	0.65 ± 0.36
P[d]		0.09	0.004	0.57	0.001
Iron supplementation					
None	330	0.54 ± 0.87	0.19 ± 0.12	0.15 ± 0.08	0.59 ± 0.34
Any	306	0.79 ± 1.21	0.20 ± 0.12	0.13 ± 0.09	0.56 ± 0.34
P[b]		0.003	0.58	0.04	0.36
Graffar index[e]					
Q1 (high SES)	118	0.49 ± 0.57	0.20 ± 0.12	0.13 ± 0.06	0.56 ± 0.29
Q2	136	0.77 ± 1.25	0.20 ± 0.12	0.14 ± 0.10	0.55 ± 0.34
Q3	140	0.74 ± 1.42	0.19 ± 0.13	0.15 ± 0.07	0.64 ± 0.38
Q4	122	0.52 ± 0.59	0.20 ± 0.12	0.14 ± 0.10	0.54 ± 0.31
Q5 (low SES)	120	0.74 ± 1.02	0.18 ± 0.10	0.14 ± 0.07	0.59 ± 0.35
P, trend[f]		0.46	0.31	0.70	0.61

Author Manuscript

This article is protected by copyright. All rights reserved.

Characteristics	N	ALA 18:3(n-3)	EPA 20:5(n-3)	DPA 22:5(n-3)	DHA 22:6(n-3)
Serum fatty acids (median, weight % of total fatty acids)					
Total *trans* fatty acids					
Q1 (1.05)	159	0.69 ± 0.94	0.18 ± 0.11	0.13 ± 0.08	0.68 ± 0.41
Q2 (1.48)	159	0.60 ± 0.65	0.19 ± 0.12	0.14 ± 0.06	0.57 ± 0.33
Q3 (1.89)	159	0.73 ± 1.61	0.18 ± 0.13	0.15 ± 0.10	0.58 ± 0.30
Q4 (2.68)	159	0.62 ± 0.75	0.21 ± 0.11	0.14 ± 0.08	0.48 ± 0.27
P, trend[f]		0.69	0.02	0.31	<0.0001

[a] Expressed as percentage of total fatty acids by weight.

[b] Wald test from linear regression models with each fatty acid as the outcome and an indicator variable for the characteristic as a predictor.

[c] Includes 7 children who were small for gestational age according to birth length.

[d] χ^2 score statistic from linear regression models with each fatty acid as the outcome and indicator variables for levels of the characteristic as predictors.

[e] Index of socioeconomic status that includes number of people in the home, presence of the father, head of household's education level and employment, home ownership, type and size of housing, running water supply, ownership of household appliances, and crowding.[27] Higher values indicate lower socioeconomic status.

[f] Wald test from linear regression models with each fatty acid as the outcome and a variable representing category-specific medians of an ordinal characteristic introduced as a continuous predictor.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table S2. Adjusted differences (95% CI)[a] in BMI-for-age Z score (BMIZ)[b] change and body composition[c] by serum n-3 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	1 y - 16 y BMIZ change[d]	Total fat mass (kg)[e]	Truncal fat mass (kg)[e]	Total lean mass (kg)[e]	% Total fat mass[e]	% Truncal fat mass[e]
ALA (18:3 n-3)						
Q1 (0.21)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (0.28)	0.02 (-0.26, 0.31)	-0.2 (-2.6, 2.2)	-0.4 (-1.8, 1.0)	-0.1 (-1.5, 1.4)	0.0 (-2.1, 2.1)	-1.1 (-2.7, 0.6)
Q3 (0.39)	-0.01 (-0.29, 0.28)	0.5 (-2.0, 3.1)	0.2 (-1.3, 1.7)	1.2 (-0.4, 2.7)	0.3 (-2.0, 2.7)	0.2 (-1.6, 2.0)
Q4 (1.32)	0.09 (-0.20, 0.39)	2.1 (-0.6, 4.9)	1.5 (-0.1, 3.1)	0.7 (-0.8, 2.2)	1.4 (-1.0, 3.8)	3.1 (1.4, 4.8)
P, trend[f]	0.48	0.08	0.02	0.46	0.19	<0.0001
EPA (20:5 n-3)						
Q1 (0.07)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (0.13)	0.12 (-0.15, 0.40)	1.1 (-1.4, 3.6)	0.2 (-1.2, 1.5)	-0.8 (-2.3, 0.7)	2.2 (0.1, 4.4)	-2.3 (-3.8, -0.7)
Q3 (0.22)	0.07 (-0.21, 0.35)	0.3 (-2.4, 3.0)	0.0 (-1.5, 1.5)	0.6 (-1.0, 2.2)	0.5 (-1.8, 2.9)	-1.6 (-3.2, 0.0)
Q4 (0.34)	-0.08 (-0.38, 0.21)	-0.3 (-2.8, 2.3)	-0.4 (-1.9, 1.1)	0.2 (-1.3, 1.7)	0.1 (-2.1, 2.2)	-2.3 (-4.0, -0.6)
P, trend	0.41	0.60	0.52	0.38	0.51	0.04
DPA (22:5 n-3)						
Q1 (0.08)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (0.11)	0.23 (-0.04, 0.50)	1.9 (-0.6, 4.3)	1.2 (-0.2, 2.6)	0.6 (-0.9, 2.1)	1.6 (-0.7, 3.8)	1.7 (0.0, 3.4)
Q3 (0.14)	0.55 (0.27, 0.82)	4.0 (1.4, 6.7)	2.4 (0.9, 3.9)	1.6 (0.0, 3.3)	3.4 (1.1, 5.8)	2.7 (1.0, 4.3)
Q4 (0.21)	0.05 (-0.22, 0.32)	2.1 (-0.4, 4.6)	1.2 (-0.2, 2.6)	0.9 (-0.7, 2.4)	1.7 (-0.5, 3.9)	1.2 (-0.5, 2.9)
P, trend	0.77	0.12	0.14	0.25	0.15	0.29
DHA (22:6 n-3)						
Q1 (0.23)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (0.43)	-0.02 (-0.30, 0.25)	0.7 (-1.9, 3.3)	0.6 (-0.9, 2.1)	-1.5 (-3.0, 0.0)	1.7 (-0.6, 4.0)	1.6 (0.0, 3.1)
Q3 (0.62)	0.11 (-0.19, 0.40)	-0.5 (-3.2, 2.3)	-0.4 (-2.0, 1.1)	0.1 (-1.3, 1.6)	-0.5 (-2.9, 2.0)	-0.9 (-2.8, 0.9)
Q4 (0.90)	0.03 (-0.28, 0.33)	-1.2 (-4.2, 1.8)	-1.0 (-2.7, 0.7)	-1.0 (-2.6, 0.6)	-0.4 (-3.0, 2.1)	-1.9 (-3.6, -0.1)
P, trend	0.75	0.33	0.16	0.47	0.45	0.006

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

Footnotes to Table S2

[a] Adjustment strategy is similar to main analyses, but without PUFA of the opposite family as covariates. In total, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[b] According to the World Health Organization Growth Reference for children ages 5-19 y.[25]

[c] Measured by dual-energy X-ray absorptiometry.

[d] Estimates are from growth curves created using mixed effects linear regression models with BMI as the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age slopes to account for within-child correlations of repeated BMI measurements.

[e] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors.

[f] From linear regression models with a variable representing medians of PUFA quartiles introduced as a continuous predictor.

This article is protected by copyright. All rights reserved.

Table S3. Body mass measured in kg[a] at 16 y by serum n-3 polyunsaturated fatty acid biomarkers at 1 years of age among children from Santiago, Chile, stratified by sex

	Total fat mass						Truncal fat mass				Total lean mass			
	Mean ± SD		Adjusted mean difference (95% CI)[b]		Mean ± SD		Adjusted mean difference (95% CI)[b]		Mean ± SD		Adjusted mean difference (95% CI)[b]	
Fatty acid quartile (median, girls/boys, weight % of total FA)	N	Girls	N	Boys	Girls	Boys	Girls	Boys	Girls	Boys	Girls	Boys	Girls	Boys
Overall	178	23.8 ± 9.4	204	16.3 ± 9.5			12.0 ± 5.3	8.3 ± 5.5			36.5 ± 5.1	50.4 ± 5.9		
ALA (18:3 n-3)														
Q1 (0.21/0.20)	51	23.7 ± 9.2	47	14.9 ± 8.5	Reference	Reference	12.1 ± 5.5	7.3 ± 5.0	Reference	Reference	36.3 ± 4.7	49.9 ± 5.4	Reference	Reference
Q2 (0.28/0.28)	42	22.5 ± 8.8	56	15.3 ± 7.8	-2.5 (-6.1, 1.0)	0.6 (-2.7, 3.9)	11.1 ± 4.9	7.4 ± 4.3	-1.7 (-3.7, 0.3)	0.2 (-1.8, 2.1)	36.5 ± 5.4	49.2 ± 5.6	0.0 (-2.0, 2.1)	-0.4 (-2.6, 1.9)
Q3 (0.42/0.38)	40	22.0 ± 7.9	50	17.6 ± 10.0	-2.3 (-5.8, 1.2)	2.5 (-1.1, 6.1)	10.8 ± 4.3	9.0 ± 5.8	-1.8 (-3.8, 0.3)	1.6 (-0.5, 3.7)	36.5 ± 5.0	51.8 ± 6.9	0.3 (-1.8, 2.3)	1.9 (-0.5, 4.2)
Q4 (1.32/1.29)	45	26.7 ± 10.7	51	17.5 ± 11.4	1.2 (-2.6, 5.0)	2.0 (-1.8, 5.9)	13.8 ± 5.7	9.4 ± 6.5	0.6 (-1.6, 2.8)	1.8 (-0.4, 3.9)	36.9 ± 5.4	50.9 ± 5.3	0.1 (-2.2, 2.4)	1.0 (-1.1, 3.1)
P, trend[c]		0.04		0.26	0.14	0.48	0.02	0.07	0.09	0.15	0.61	0.31	0.96	0.44
P, interaction[d]		0.50			0.57		0.76		0.85		0.73		0.63	
EPA (20:5 n-3)														
Q1 (0.07/0.07)	48	24.4 ± 11.0	47	14.2 ± 9.0	Reference	Reference	12.5 ± 5.9	7.3 ± 5.2	Reference	Reference	36.7 ± 5.7	49.5 ± 5.8	Reference	Reference
Q2 (0.13/0.13)	42	23.7 ± 8.9	53	17.9 ± 8.8	-2.4 (-6.2, 1.4)	2.9 (-0.4, 6.2)	11.8 ± 4.9	8.9 ± 4.9	-1.7 (-3.7, 0.3)	1.1 (-0.8, 3.0)	35.5 ± 4.8	49.7 ± 5.5	-1.3 (-3.4, 0.8)	-0.6 (-2.9, 1.7)
Q3 (0.22/0.22)	44	23.0 ± 8.6	55	16.9 ± 10.7	-2.1 (-6.3, 2.1)	1.8 (-1.9, 5.5)	11.6 ± 4.9	8.8 ± 6.3	-1.4 (-3.7, 0.9)	0.8 (-1.3, 2.9)	36.7 ± 4.5	51.6 ± 6.5	-0.2 (-2.4, 2.0)	1.0 (-1.4, 3.4)
Q4 (0.33/0.34)	44	24.1 ± 8.8	49	15.9 ± 9.0	-0.3 (-4.0, 3.4)	-1.0 (-4.6, 2.7)	12.2 ± 5.3	7.9 ± 5.2	-0.1 (-2.3, 2.0)	-1.2 (-3.3, 1.0)	37.1 ± 5.1	50.9 ± 5.5	0.4 (-1.7, 2.5)	-0.6 (-3.0, 1.8)
P, trend		0.85		0.70	0.93	0.30	0.87	0.83	0.82	0.15	0.43	0.11	0.40	0.97
P, interaction		0.69			0.43		0.79		0.24		0.55		0.56	
DPA (22:5 n-3)														
Q1 (0.08/0.07)	39	21.4 ± 7.8	52	14.0 ± 8.6	Reference	Reference	10.7 ± 4.4	6.9 ± 5.0	Reference	Reference	35.5 ± 4.3	49.5 ± 6.7	Reference	Reference
Q2 (0.11/0.11)	52	23.6 ± 8.7	44	15.9 ± 9.4	2.5 (-1.1, 6.1)	2.8 (-0.6, 6.3)	12.0 ± 5.1	8.1 ± 5.4	1.5 (-0.6, 3.6)	1.8 (-0.2, 3.8)	36.4 ± 4.9	50.3 ± 5.0	0.9 (-1.1, 2.9)	1.0 (-1.4, 3.4)
Q3 (0.14/0.14)	38	23.9 ± 9.3	60	19.5 ± 11.2	1.5 (-2.5, 5.5)	5.6 (2.1, 9.0)	12.1 ± 5.2	10.1 ± 6.4	0.9 (-1.4, 3.2)	3.4 (1.4, 5.4)	36.5 ± 5.6	51.6 ± 6.2	0.4 (-1.8, 2.6)	2.1 (-0.3, 4.6)
Q4 (0.21/0.20)	49	25.8 ± 11.0	48	15.3 ± 7.1	3.4 (-0.6, 7.3)	0.9 (-2.2, 3.9)	13.0 ± 6.0	7.7 ± 4.2	1.9 (-0.3, 4.1)	0.6 (-1.2, 2.3)	37.5 ± 5.3	50.2 ± 5.2	1.4 (-0.8, 3.6)	0.1 (-2.3, 2.5)
P, trend		0.05		0.31	0.16	0.77	0.07	0.30	0.18	0.75	0.06	0.45	0.30	0.96
P, interaction		0.35			0.36		0.46		0.40		0.50		0.45	
DHA (22:6 n-3)														
Q1 (0.20/0.24)	37	23.6 ± 8.2	55	16.2 ± 10.9	Reference	Reference	12.0 ± 4.8	8.2 ± 6.2	Reference	Reference	36.9 ± 4.5	50.9 ± 6.2	Reference	Reference
Q2 (0.43/0.43)	43	23.5 ± 9.2	57	16.8 ± 8.8	0.1 (-3.8, 4.0)	2.4 (-1.3, 6.0)	12.2 ± 5.3	8.8 ± 5.1	0.1 (-2.1, 2.4)	1.4 (-0.7, 3.5)	36.0 ± 5.0	48.8 ± 6.1	-1.0 (-3.1, 1.2)	-1.6 (-3.6, 0.5)
Q3 (0.62/0.61)	50	24.4 ± 10.4	45	15.3 ± 8.6	-0.3 (-4.1, 3.5)	-0.5 (-5.2, 4.1)	12.2 ± 5.9	7.6 ± 4.9	-0.4 (-2.7, 1.8)	-0.6 (-3.3, 2.0)	37.3 ± 6.0	50.8 ± 4.8	0.5 (-1.7, 2.7)	0.0 (-2.4, 2.3)
Q4 (0.89/0.94)	48	23.6 ± 9.5	47	16.9 ± 9.6	-1.9 (-6.6, 2.9)	0.0 (-5.2, 5.2)	11.7 ± 5.0	8.4 ± 5.6	-1.3 (-4.0, 1.3)	-0.5 (-3.5, 2.5)	35.9 ± 4.5	51.5 ± 6.0	-1.9 (-4.3, 0.5)	-0.5 (-3.1, 2.2)
P, trend		0.91		0.87	0.40	0.84	0.71	0.95	0.27	0.57	0.47	0.29	0.16	0.92
P, interaction		0.96			0.68		0.84		0.77		0.20		0.39	

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-3 PUFA are adjusted for LA and total long-chain n-6 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as a continuous predictor.

[d] From linear regression models with an indicator for male sex as a predictor and cross-product terms between the indicator and all other predictors in the model.

This article is protected by copyright. All rights reserved.

Table S4. Percent total and truncal fat[a] at 16 y by serum n-3 polyunsaturated fatty acid biomarkers at 1 years of age among children from Santiago, Chile, stratified by sex

	% Total fat						% Truncal fat			
	Mean ± SD				Adjusted mean difference (95% CI)[b]		Mean ± SD		Adjusted mean difference (95% CI)[b]	
Fatty acid quartile (median, girls/boys, weight % of total FA)	N	Girls	N	Boys	Girls	Boys	Girls	Boys	Girls	Boys
Overall	178	36.8 ± 7.2	204	22.3 ± 8.9			49.6 ± 5.2	49.0 ± 6.4		
ALA (18:3 n-3)										
Q1 (0.21/0.20)	51	36.9 ± 7.3	47	21.3 ± 8.4	Reference	Reference	49.9 ± 5.8	47.4 ± 6.6	Reference	Reference
Q2 (0.28/0.28)	42	35.6 ± 6.4	56	22.0 ± 7.7	-2.1 (-4.8, 0.6)	0.7 (-2.6, 4.0)	48.6 ± 5.3	46.8 ± 5.2	-1.7 (-3.9, 0.5)	-0.7 (-3.1, 1.7)
Q3 (0.42/0.38)	40	35.5 ± 6.9	50	23.1 ± 9.0	-1.8 (-4.7, 1.1)	1.5 (-2.0, 5.0)	48.6 ± 4.3	49.4 ± 7.0	-2.1 (-4.2, 0.0)	1.9 (-0.9, 4.7)
Q4 (1.32/1.29)	45	39.0 ± 7.7	51	22.9 ± 10.5	0.9 (-2.1, 3.9)	0.9 (-2.8, 4.6)	51.2 ± 4.9	52.5 ± 5.1	0.7 (-1.5, 3.0)	4.9 (2.4, 7.5)
P, trend[c]		0.03		0.54	0.13	0.88	0.03	<0.0001	0.06	<0.0001
P, interaction[d]			0.39			0.38		0.01		0.02
EPA (20:5 n-3)										
Q1 (0.07/0.07)	48	36.9 ± 7.9	47	20.2 ± 8.5	Reference	Reference	50.6 ± 4.9	50.1 ± 6.2	Reference	Reference
Q2 (0.13/0.13)	42	37.6 ± 6.6	53	24.5 ± 8.2	-0.8 (-3.7, 2.1)	3.6 (0.6, 6.7)	48.7 ± 5.0	48.4 ± 6.4	-2.3 (-4.4, -0.3)	-2.2 (-4.6, 0.1)
Q3 (0.22/0.22)	44	36.1 ± 7.2	55	22.4 ± 10.0	-1.2 (-4.3, 1.9)	1.6 (-1.9, 5.1)	49.4 ± 4.9	49.8 ± 6.2	-1.8 (-4.1, 0.5)	-2.0 (-4.2, 0.2)
Q4 (0.33/0.34)	44	36.8 ± 6.9	49	21.9 ± 8.3	-0.1 (-3.1, 2.9)	-0.5 (-4.0, 3.0)	49.6 ± 6.0	47.7 ± 6.5	-0.3 (-2.6, 2.0)	-5.2 (-7.8, -2.7)
P, trend		0.74		0.90	0.96	0.29	0.64	0.17	0.86	0.0002
P, interaction			0.75			0.44		0.48		0.004
DPA (22:5 n-3)										
Q1 (0.08/0.07)	39	35.3 ± 7.0	52	20.2 ± 8.1	Reference	Reference	49.5 ± 4.6	47.1 ± 6.6	Reference	Reference
Q2 (0.11/0.11)	52	36.8 ± 7.1	44	21.9 ± 9.1	1.7 (-1.3, 4.8)	2.5 (-0.9, 5.9)	49.8 ± 4.8	49.2 ± 6.3	0.8 (-1.3, 2.9)	3.0 (0.5, 5.4)
Q3 (0.14/0.14)	38	37.2 ± 6.9	60	24.9 ± 10.0	1.5 (-1.8, 4.8)	4.7 (1.5, 7.9)	49.7 ± 5.5	50.6 ± 5.9	1.0 (-1.1, 3.2)	4.1 (1.7, 6.5)
Q4 (0.21/0.20)	49	37.9 ± 7.5	48	21.8 ± 7.4	2.2 (-1.1, 5.4)	1.3 (-1.8, 4.4)	49.5 ± 5.9	48.9 ± 6.4	0.7 (-1.5, 2.9)	1.8 (-0.7, 4.3)
P, trend		0.12		0.26	0.26	0.56	0.97	0.18	0.67	0.30
P, interaction			0.80			0.71		0.30		0.62

This article is protected by copyright. All rights reserved.

DHA (22:6 n-3)												
Q1 (0.20/0.24)	37	36.6 ± 7.1	55	21.7 ± 10.1	Reference		Reference		50.1 ± 5.3	48.6 ± 6.8	Reference	Reference
Q2 (0.43/0.43)	43	36.8 ± 7.8	57	23.6 ± 8.9	0.5 (-2.9, 3.9)		3.6 (0.2, 7.1)		51.0 ± 4.3	50.6 ± 6.0	0.8 (-1.4, 2.9)	2.0 (-0.2, 4.3)
Q3 (0.62/0.61)	50	36.6 ± 7.0	45	21.3 ± 8.2	-0.9 (-4.2, 2.5)		-0.2 (-4.5, 4.1)		48.9 ± 5.8	48.7 ± 6.6	-0.9 (-3.4, 1.7)	-1.3 (-4.2, 1.5)
Q4 (0.89/0.94)	48	37.2 ± 7.0	47	22.5 ± 8.0	-0.6 (-4.4, 3.1)		0.1 (-4.5, 4.7)		48.8 ± 5.0	47.8 ± 5.8	-0.7 (-3.6, 2.2)	-3.5 (-6.3, -0.7)
P, trend		0.70		0.96	0.64		0.78		0.08	0.26	0.48	0.005
P, interaction		0.83			0.94				0.75		0.14	

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-3 PUFA are adjusted for LA and total long-chain n-6 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as a continuous predictor.

[d] From linear regression models with an indicator for male sex as a predictor and cross-product terms between the indicator and all other predictors in the model.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table S5. Cross-sectional unadjusted analyses of serum n-6 polyunsaturated fatty acid biomarkers[a] by categories of sociodemographic and other characteristics among infants from Santiago, Chile

Characteristics	N	N-6					Desaturase indices	
		LA 18:2(n-6)	GLA 18:3(n-6)	DGLA 20:3(n-6)	AA 20:4(n-6)	N-6:N-3 ratio	Δ6-desaturase activity index (GLA/LA)	Δ5-desaturase activity index (AA/DGLA)
Overall	636	23.74 ± 6.00	0.20 ± 0.36	0.69 ± 0.24	1.56 ± 0.58	22.66 ± 12.14	0.009 ± 0.017	2.93 ± 5.01
Sociodemographic characteristics								
Sex								
Female	296	23.75 ± 5.91	0.20 ± 0.38	0.69 ± 0.25	1.54 ± 0.60	22.63 ± 12.91	0.009 ± 0.017	3.03 ± 5.59
Male	340	23.74 ± 6.09	0.19 ± 0.35	0.69 ± 0.23	1.57 ± 0.56	22.68 ± 11.44	0.009 ± 0.017	2.85 ± 4.45
P[b]		0.99	0.82	0.99	0.49	0.96	0.83	0.64
Birth length								
Average for gestational age[c]	425	23.62 ± 5.92	0.21 ± 0.41	0.67 ± 0.23	1.51 ± 0.58	22.82 ± 12.02	0.010 ± 0.019	2.76 ± 4.41
Large for gestational age	211	24.00 ± 6.17	0.16 ± 0.23	0.72 ± 0.26	1.66 ± 0.57	22.33 ± 12.39	0.007 ± 0.011	3.28 ± 6.04
P[b]		0.46	0.03	0.01	0.003	0.64	0.04	0.27
Birth weight								
Average for gestational age	467	23.63 ± 6.04	0.20 ± 0.38	0.67 ± 0.23	1.52 ± 0.58	22.91 ± 12.52	0.009 ± 0.018	2.95 ± 5.27
Large for gestational age	169	24.04 ± 5.91	0.18 ± 0.32	0.73 ± 0.26	1.66 ± 0.57	21.96 ± 11.02	0.008 ± 0.014	2.90 ± 4.22
P[b]		0.44	0.46	0.01	0.005	0.35	0.36	0.91
Breastfeeding								
Breastfeeding <6 mo	206	23.65 ± 6.77	0.20 ± 0.44	0.70 ± 0.25	1.43 ± 0.52	22.42 ± 11.75	0.009 ± 0.018	2.98 ± 6.81
Mixed bottle/breastfeeding, ≥6 mo	231	23.09 ± 5.50	0.20 ± 0.34	0.69 ± 0.24	1.51 ± 0.53	22.96 ± 12.94	0.009 ± 0.016	2.71 ± 3.53
Exclusive breastfeeding, ≥6 mo	189	24.59 ± 5.57	0.19 ± 0.30	0.67 ± 0.22	1.75 ± 0.65	22.49 ± 11.86	0.009 ± 0.016	3.21 ± 4.33
P[d]		0.02	0.97	0.30	<0.0001	0.89	0.95	0.43

Author Manuscript

This article is protected by copyright. All rights reserved.

Iron supplementation								
None	330	21.51 ± 5.21	0.20 ± 0.30	0.77 ± 0.23	1.74 ± 0.56	22.26 ± 12.22	0.010 ± 0.015	2.89 ± 4.87
Any	306	26.15 ± 5.88	0.19 ± 0.42	0.60 ± 0.21	1.36 ± 0.53	23.09 ± 12.05	0.008 ± 0.018	2.98 ± 5.16
P[b]		<0.0001	0.61	<0.0001	<0.0001	0.39	0.14	0.83
Graffar index[e]								
Q1 (high SES)	118	22.97 ± 6.00	0.13 ± 0.16	0.70 ± 0.23	1.50 ± 0.54	22.72 ± 10.50	0.006 ± 0.008	2.90 ± 4.38
Q2	136	23.92 ± 5.89	0.17 ± 0.32	0.68 ± 0.23	1.55 ± 0.57	22.35 ± 11.47	0.008 ± 0.017	2.46 ± 1.40
Q3	140	23.92 ± 6.23	0.21 ± 0.36	0.72 ± 0.25	1.61 ± 0.61	21.97 ± 13.61	0.009 ± 0.014	2.83 ± 4.21
Q4	122	24.14 ± 6.15	0.23 ± 0.42	0.68 ± 0.24	1.56 ± 0.51	25.01 ± 14.61	0.010 ± 0.020	3.52 ± 7.13
Q5 (low SES)	120	23.69 ± 5.74	0.24 ± 0.47	0.67 ± 0.24	1.56 ± 0.66	21.35 ± 9.31	0.011 ± 0.021	3.04 ± 6.31
P, trend[f]		0.45	0.01	0.33	0.61	0.87	0.01	0.38
Serum fatty acids (median, weight % of total fatty acids)								
Total *trans* fatty acids								
Q1 (1.05)	159	28.80 ± 4.38	0.20 ± 0.33	0.64 ± 0.20	1.64 ± 0.67	25.72 ± 14.07	0.007 ± 0.012	3.11 ± 5.38
Q2 (1.48)	159	24.98 ± 4.91	0.22 ± 0.36	0.72 ± 0.26	1.64 ± 0.56	24.75 ± 14.89	0.009 ± 0.014	3.10 ± 4.96
Q3 (1.89)	159	22.22 ± 5.00	0.19 ± 0.34	0.73 ± 0.24	1.59 ± 0.52	21.63 ± 9.64	0.009 ± 0.018	3.10 ± 6.31
Q4 (2.68)	159	18.96 ± 4.89	0.18 ± 0.42	0.66 ± 0.24	1.37 ± 0.52	18.53 ± 6.88	0.010 ± 0.022	2.42 ± 2.67
P, trend[f]		<0.0001	0.49	0.95	<0.0001	<0.0001	0.20	0.10

[a] Expressed as percentage of total fatty acids by weight.
[b] Wald test from linear regression models with each fatty acid as the outcome and an indicator variable for the characteristic as a predictor.
[c] Includes 7 children who were small for gestational age according to birth length.
[d] χ^2 score statistic from linear regression models with each fatty acid as the outcome and indicator variables for levels of the characteristic as predictors.
[e] Index of socioeconomic status that includes number of people in the home, presence of the father, head of household's education level and employment, home ownership, type and size of housing, running water supply, ownership of household appliances, and crowding.[27] Higher values indicate lower socioeconomic status.
[f] Wald test from linear regression models with each fatty acid as the outcome and a variable representing category-specific medians of an ordinal characteristic introduced as a continuous predictor

Author Manuscript

This article is protected by copyright. All rights reserved.

Table S6. Adjusted differences (95% CI)[a] in BMI-for-age Z score (BMIZ)[b] change and body composition[c] by serum n-6 polyunsaturated fatty acid biomarkers at 1 year of age among children from Santiago, Chile

Fatty acid quartile (median, weight % of total FA)	1 y - 16 y BMIZ change (95% CI)[d]	Total fat mass (kg)[e]	Truncal fat mass (kg)[e]	Total lean mass (kg)[e]	% Total fat mass[e]	% Truncal fat mass[e]
LA (18:2 n-6)						
Q1 (16.53)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (21.31)	0.34 (0.03, 0.64)	1.6 (-1.1, 4.3)	1.1 (-0.5, 2.6)	0.4 (-1.3, 2.1)	1.9 (-0.5, 4.2)	1.0 (-0.8, 2.8)
Q3 (25.87)	0.22 (-0.09, 0.54)	1.5 (-1.3, 4.3)	1.0 (-0.6, 2.5)	1.4 (-0.2, 3.1)	1.4 (-1.1, 3.8)	1.6 (-0.2, 3.4)
Q4 (30.97)	0.12 (-0.25, 0.50)	1.3 (-2.0, 4.6)	1.0 (-0.9, 2.8)	0.5 (-1.4, 2.5)	1.3 (-1.5, 4.0)	1.6 (-0.3, 3.6)
P, trend[f]	0.66	0.47	0.33	0.45	0.44	0.09
GLA (18:3 n-6)						
Q1 (0.00)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (0.07)	0.08 (-0.19, 0.36)	1.3 (-1.2, 3.8)	0.9 (-0.6, 2.3)	0.3 (-1.3, 1.9)	0.7 (-1.6, 3.0)	1.1 (-0.7, 2.9)
Q3 (0.11)	0.03 (-0.26, 0.33)	1.5 (-1.1, 4.2)	0.8 (-0.8, 2.3)	0.7 (-0.9, 2.4)	0.9 (-1.4, 3.3)	-0.3 (-2.0, 1.5)
Q4 (0.42)	0.17 (-0.11, 0.45)	2.4 (0.1, 4.8)	1.3 (-0.1, 2.6)	0.0 (-1.6, 1.5)	2.5 (0.3, 4.7)	0.0 (-1.6, 1.6)
P, trend	0.25	0.09	0.15	0.64	0.02	0.68
DGLA (20:3 n-6)						
Q1 (0.44)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (0.61)	0.26 (-0.01, 0.54)	2.2 (-0.4, 4.8)	1.4 (-0.1, 2.9)	1.1 (-0.3, 2.6)	2.0 (-0.3, 4.3)	1.5 (-0.1, 3.1)
Q3 (0.76)	0.14 (-0.14, 0.41)	0.5 (-2.2, 3.1)	0.4 (-1.1, 1.8)	1.2 (-0.4, 2.7)	0.3 (-1.9, 2.6)	1.0 (-0.7, 2.7)
Q4 (0.96)	-0.11 (-0.40, 0.18)	0.5 (-2.3, 3.3)	0.3 (-1.3, 1.8)	0.7 (-1.0, 2.4)	0.2 (-2.2, 2.6)	-0.2 (-2.1, 1.6)
P, trend	0.30	0.88	0.81	0.54	0.69	0.53
AA (20:4 n-6)						
Q1 (0.94)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (1.31)	0.27 (-0.03, 0.57)	0.5 (-2.4, 3.3)	0.3 (-1.4, 1.9)	1.5 (-0.1, 3.1)	0.0 (-2.5, 2.5)	0.1 (-1.6, 1.8)
Q3 (1.65)	0.24 (-0.07, 0.56)	0.2 (-2.9, 3.4)	0.0 (-1.7, 1.8)	1.5 (-0.2, 3.3)	-0.5 (-3.2, 2.1)	-0.4 (-2.3, 1.4)
Q4 (2.27)	0.34 (0.00, 0.67)	1.5 (-2.0, 5.1)	0.6 (-1.4, 2.6)	0.7 (-1.2, 2.6)	1.5 (-1.4, 4.5)	-0.9 (-2.9, 1.1)
P, trend	0.09	0.40	0.57	0.76	0.27	0.30

Author Manuscript

This article is protected by copyright. All rights reserved.

N-6:N-3 ratio						
Q1 (12.7:1)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (18.3:1)	0.06 (-0.22, 0.35)	-0.9 (-3.4, 1.7)	-1.0 (-2.5, 0.4)	-0.1 (-1.6, 1.3)	-0.3 (-2.5, 1.8)	-3.4 (-5.0, -1.8)
Q3 (22.9:1)	0.06 (-0.23, 0.35)	0.6 (-2.2, 3.4)	0.0 (-1.7, 1.6)	1.5 (-0.1, 3.0)	0.1 (-2.2, 2.5)	-2.1 (-3.7, -0.4)
Q4 (32.0:1)	0.00 (-0.28, 0.29)	-0.1 (-2.6, 2.5)	-0.3 (-1.8, 1.2)	-0.9 (-2.5, 0.7)	0.6 (-1.7, 2.9)	-1.8 (-3.4, -0.2)
P, trend	0.96	0.81	>0.99	0.40	0.51	0.20
Desaturase activity indices						
Δ6-Desaturase index (GLA/LA)						
Q1 (0.000)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (0.003)	0.21 (-0.07, 0.49)	1.5 (-1.1, 4.1)	0.9 (-0.6, 2.4)	0.5 (-1.1, 2.1)	1.1 (-1.3, 3.5)	0.4 (-1.4, 2.2)
Q3 (0.005)	0.01 (-0.28, 0.30)	0.9 (-1.7, 3.6)	0.3 (-1.2, 1.9)	0.6 (-1.0, 2.1)	0.4 (-2.0, 2.7)	-0.8 (-2.6, 1.0)
Q4 (0.017)	0.20 (-0.07, 0.47)	2.6 (0.2, 4.9)	1.3 (-0.1, 2.7)	-0.1 (-1.6, 1.5)	2.6 (0.5, 4.7)	-0.2 (-1.7, 1.4)
P, trend	0.27	0.05	0.10	0.65	0.01	0.78
Δ5-Desaturase index (AA/DGLA)						
Q1 (1.57)	Reference	Reference	Reference	Reference	Reference	Reference
Q2 (1.94)	0.06 (-0.22, 0.34)	-0.5 (-3.0, 2.0)	-0.4 (-1.8, 1.1)	0.6 (-1.0, 2.1)	-0.3 (-2.6, 2.0)	-1.0 (-2.7, 0.7)
Q3 (2.42)	0.14 (-0.16, 0.44)	0.7 (-2.1, 3.4)	0.3 (-1.3, 1.9)	0.6 (-1.0, 2.2)	0.5 (-1.9, 2.8)	-0.8 (-2.5, 0.9)
Q4 (3.21)	0.02 (-0.29, 0.33)	-0.2 (-3.1, 2.7)	-0.4 (-2.1, 1.3)	-0.2 (-1.8, 1.4)	-0.1 (-2.6, 2.4)	-1.6 (-3.5, 0.2)
P, trend	0.91	0.95	0.79	0.73	0.94	0.11

[a] Adjustment strategy is similar to main analyses, but without PUFA of the opposite family as covariates. In total, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[b] According to the World Health Organization Growth Reference for children ages 5-19 y.[25]

[c] Measured by dual-energy X-ray absorptiometry.

[d] Estimates are from growth curves created using mixed effects linear regression models with BMI as the outcome, and predictors that included indicator variables for each PUFA quartile, linear and cubic spline terms for age, and interaction terms between the quartiles and age terms. All models included random intercepts and age slopes to account for within-child correlations of repeated BMI measurements.

[e] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors.

[f] From linear regression models with a variable representing medians of PUFA quartiles introduced as a continuous predictor.

Author Manuscript

This article is protected by copyright. All rights reserved.

Table S7. Body mass measured in kg[a] at 16 y by serum n-6 polyunsaturated fatty acid biomarkers at 1 years of age among children from Santiago, Chile, stratified by sex

	Total fat mass						Truncal fat mass				Total lean mass			
	Mean ± SD				Adjusted mean difference (95% CI)[b]		Mean ± SD		Adjusted mean difference (95% CI)		Mean ± SD		Adjusted mean difference (95% CI)	
Fatty acid quartile (median, girls/boys, weight % of total FA)	N	Girls	N	Boys	Girls	Boys	Girls	Boys	Girls	Boys	Girls	Boys	Girls	Boys
N-6														
LA (18:2 n-6)														
Q1 (17.19/16.24)	47	25.1 ± 10.6	51	13.4 ± 8.8	Reference	Reference	12.6 ± 5.5	6.7 ± 5.2	Reference	Reference	36.7 ± 6.0	48.8 ± 5.7	Reference	Reference
Q2 (21.28/21.46)	45	22.5 ± 8.3	50	18.3 ± 9.6	-1.9 (-5.8, 2.0)	4.8 (1.0, 8.5)	11.5 ± 4.9	9.3 ± 5.7	-0.7 (-2.9, 1.6)	2.7 (0.5, 4.9)	36.6 ± 4.9	50.4 ± 6.5	-0.1 (-2.4, 2.3)	0.7 (-1.6, 3.1)
Q3 (25.95/25.80)	36	23.7 ± 9.1	53	16.9 ± 9.3	-1.2 (-5.1, 2.7)	4.3 (0.5, 8.2)	12.0 ± 5.3	8.5 ± 5.2	-0.4 (-2.6, 1.8)	2.4 (0.2, 4.6)	36.5 ± 4.4	51.8 ± 5.2	-0.2 (-2.6, 2.2)	2.5 (0.2, 4.8)
Q4 (31.19/30.88)	50	23.7 ± 9.4	50	16.7 ± 9.7	-1.7 (-6.3, 2.8)	3.7 (-1.2, 8.6)	11.9 ± 5.4	8.6 ± 5.6	-0.9 (-3.4, 1.7)	2.3 (-0.5, 5.2)	36.3 ± 4.9	50.7 ± 5.9	-0.5 (-3.2, 2.3)	1.0 (-1.9, 3.9)
P, trend[c]		0.65		0.15	0.53	0.17	0.61	0.16	0.56	0.14	0.72	0.06	0.74	0.35
P, interaction[d]		0.19			0.15		0.18		0.13		0.18		0.36	
GLA (18:3 n-6)														
Q1 (0.00/0.00)	36	21.3 ± 6.9	50	16.0 ± 9.7	Reference	Reference	10.6 ± 3.8	8.2 ± 5.7	Reference	Reference	35.7 ± 4.5	50.6 ± 6.0	Reference	Reference
Q2 (0.07/0.07)	38	25.3 ± 11.3	51	15.5 ± 9.0	2.3 (-1.4, 6.0)	-0.5 (-4.1, 3.2)	13.0 ± 6.2	7.9 ± 5.2	1.6 (-0.5, 3.7)	-0.2 (-2.3, 1.9)	37.0 ± 5.8	50.4 ± 5.4	0.2 (-2.0, 2.4)	0.4 (-2.0, 2.7)
Q3 (0.11/0.11)	49	24.3 ± 9.8	47	16.2 ± 10.8	2.5 (-1.0, 6.1)	-0.4 (-4.1, 3.3)	12.1 ± 5.5	8.3 ± 6.2	1.2 (-0.8, 3.3)	-0.3 (-2.5, 1.9)	36.8 ± 5.4	50.9 ± 6.6	0.5 (-1.7, 2.7)	0.0 (-2.4, 2.5)
Q4 (0.37/0.43)	55	24.0 ± 8.9	56	17.4 ± 8.7	2.8 (-0.5, 6.0)	3.9 (0.3, 7.5)	12.2 ± 5.1	8.6 ± 5.0	1.8 (-0.1, 3.6)	2.0 (-0.1, 4.1)	36.5 ± 4.5	49.9 ± 5.7	0.1 (-1.8, 2.0)	-0.4 (-2.8, 2.1)
P, trend		0.56		0.27	0.28	0.02	0.53	0.55	0.21	0.03	0.86	0.45	0.91	0.68
P, interaction		0.73			0.28		0.97		0.44		0.97		0.79	
DGLA (20:3 n-6)														
Q1 (0.44/0.44)	45	22.6 ± 7.7	44	16.2 ± 11.4	Reference	Reference	11.5 ± 4.3	8.1 ± 6.3	Reference	Reference	35.4 ± 4.0	50.7 ± 5.8	Reference	Reference
Q2 (0.61/0.61)	42	24.4 ± 9.1	56	17.7 ± 9.1	2.2 (-1.2, 5.7)	1.7 (-2.3, 5.8)	12.5 ± 5.4	9.1 ± 5.4	1.4 (-0.6, 3.4)	1.1 (-1.2, 3.4)	36.8 ± 4.9	50.7 ± 5.1	1.8 (-0.1, 3.7)	-0.4 (-2.5, 1.8)
Q3 (0.75/0.76)	44	24.4 ± 10.2	50	14.8 ± 7.5	1.2 (-2.3, 4.8)	-0.3 (-4.0, 3.5)	12.3 ± 5.3	7.4 ± 4.4	0.7 (-1.3, 2.7)	0.1 (-2.0, 2.2)	36.9 ± 5.2	50.4 ± 6.3	1.5 (-0.4, 3.4)	0.0 (-2.4, 2.5)
Q4 (0.97/0.96)	47	23.8 ± 10.4	54	16.3 ± 9.9	0.8 (-3.1, 4.7)	0.3 (-3.9, 4.5)	11.8 ± 6.0	8.3 ± 5.7	0.2 (-1.9, 2.4)	0.5 (-1.9, 2.8)	37.0 ± 5.9	50.0 ± 6.5	1.4 (-0.7, 3.6)	-0.7 (-3.3, 1.8)
P, trend		0.56		0.70	0.86	0.85	0.89	0.77	0.94	0.96	0.15	0.51	0.28	0.62
P, interaction		0.49			0.80		0.76		0.93		0.76		0.28	

Author Manuscript

This article is protected by copyright. All rights reserved.

AA (20:4 n-6)																
Q1 (0.94/0.95)	42	23.3 ± 8.5	45	16.0 ± 9.8	Reference		Reference		11.9 ± 4.9	8.2 ± 5.7	Reference		Reference		35.8 ± 4.8	48.9 ± 4.9	Reference		Reference	
Q2 (1.31/1.31)	51	21.9 ± 8.4	56	16.9 ± 9.6	-0.2	(-4.4, 4.0)	1.0	(-2.7, 4.7)	11.2 ± 4.9	8.6 ± 5.5	0.3	(-2.1, 2.8)	0.2	(-1.8, 2.3)	36.6 ± 4.9	50.9 ± 6.9	1.1	(-1.3, 3.6)	1.9	(-0.4, 4.1)
Q3 (1.69/1.63)	46	24.4 ± 9.9	52	14.3 ± 9.0	2.1	(-2.5, 6.7)	-2.4	(-6.1, 1.4)	12.1 ± 5.4	7.3 ± 5.2	1.0	(-1.6, 3.6)	-1.5	(-3.6, 0.7)	36.8 ± 5.3	51.0 ± 5.2	0.9	(-1.7, 3.5)	1.6	(-0.6, 3.9)
Q4 (2.30/2.23)	39	26.2 ± 10.6	51	17.9 ± 9.5	1.6	(-3.8, 7.0)	0.6	(-4.3, 5.5)	13.0 ± 6.0	9.0 ± 5.5	1.0	(-2.1, 4.2)	-0.1	(-2.8, 2.7)	36.9 ± 5.3	50.7 ± 6.0	-0.8	(-4.0, 2.4)	1.1	(-1.5, 3.7)
P, trend		0.08		0.47	0.40		0.96		0.24	0.60	0.44		0.77		0.33	0.22	0.46		0.70	
P, interaction		0.42			0.52				0.61		0.45				0.61		0.42			
N-6:N-3 ratio																				
Q1 (12.6/12.9)	46	25.0 ± 10.2	45	16.5 ± 10.1	Reference		Reference		12.9 ± 5.5	8.8 ± 5.9	Reference		Reference		36.9 ± 5.4	50.3 ± 5.1	Reference		Reference	
Q2 (17.9/18.6)	40	23.1 ± 7.9	58	15.5 ± 9.3	0.9	(-3.7, 5.5)	1.8	(-3.3, 7.0)	11.4 ± 4.2	7.6 ± 5.3	-0.1	(-2.8, 2.6)	0.9	(-2.1, 3.9)	36.4 ± 4.6	50.1 ± 5.3	-0.4	(-3.2, 2.4)	1.2	(-1.3, 3.8)
Q3 (22.9/22.8)	46	23.2 ± 10.5	48	18.1 ± 10.2	3.0	(-2.6, 8.7)	4.3	(-1.1, 9.8)	11.5 ± 5.9	9.3 ± 5.8	0.9	(-2.4, 4.2)	2.7	(-0.6, 6.0)	36.3 ± 5.6	53.1 ± 5.9	0.0	(-3.2, 3.2)	4.6	(1.9, 7.3)
Q4 (31.7/32.1)	46	23.8 ± 8.7	53	15.3 ± 8.4	4.6	(-2.0, 11.3)	4.0	(-2.0, 10.1)	12.1 ± 5.2	7.6 ± 4.8	2.0	(-2.0, 5.9)	2.5	(-1.1, 6.1)	36.5 ± 4.6	48.4 ± 6.3	0.2	(-3.6, 4.0)	-0.2	(-3.6, 3.2)
P, trend		0.63		0.68	0.13		0.19		0.59	0.48	0.24		0.13		0.74	0.14	0.84		0.53	
P, interaction		0.95			0.76				0.92		0.92				0.38		0.56			
Desaturase activity indices																				
Δ6-Desaturase index (GLA/LA)																				
Q1 (0.000/0.000)	41	20.9 ± 7.3	51	16.0 ± 9.3	Reference		Reference		10.5 ± 4.2	8.2 ± 5.5	Reference		Reference		35.5 ± 4.3	50.8 ± 5.9	Reference		Reference	
Q2 (0.003/0.003)	37	25.4 ± 11.2	45	16.6 ± 9.6	1.9	(-1.9, 5.6)	0.5	(-3.3, 4.3)	12.9 ± 6.2	8.5 ± 5.6	1.2	(-1.0, 3.4)	0.2	(-2.0, 2.4)	36.7 ± 6.0	51.3 ± 5.5	0.0	(-2.1, 2.1)	0.5	(-1.8, 2.8)
Q3 (0.005/0.005)	41	24.1 ± 9.7	55	15.2 ± 10.2	2.3	(-1.3, 5.8)	-0.4	(-4.1, 3.3)	12.0 ± 5.2	7.7 ± 5.8	1.1	(-1.0, 3.1)	-0.4	(-2.5, 1.8)	37.2 ± 5.4	50.0 ± 5.8	1.1	(-1.1, 3.2)	-0.2	(-2.4, 2.0)
Q4 (0.015/0.020)	59	24.5 ± 9.0	53	17.4 ± 8.9	3.5	(0.3, 6.7)	2.7	(-0.9, 6.3)	12.5 ± 5.2	8.7 ± 5.1	2.2	(0.3, 4.0)	1.3	(-0.7, 3.4)	36.6 ± 4.7	49.8 ± 6.3	0.5	(-1.3, 2.3)	-1.2	(-3.7, 1.4)
P, trend		0.24		0.37	0.07		0.12		0.21	0.63	0.05		0.19		0.54	0.27	0.68		0.27	
P, interaction		0.85			0.97				0.59		0.76				0.59		0.26			
Δ5-Desaturase index (AA/DGLA)																				
Q1 (1.57/1.57)	43	23.1 ± 8.6	59	16.1 ± 10.1	Reference		Reference		11.7 ± 4.9	8.3 ± 5.8	Reference		Reference		37.3 ± 5.6	48.7 ± 6.4	Reference		Reference	
Q2 (1.93/1.94)	45	21.9 ± 8.1	52	16.3 ± 9.1	0.1	(-3.8, 4.0)	-1.1	(-4.4, 2.2)	11.2 ± 4.7	8.3 ± 5.4	0.1	(-2.2, 2.3)	-0.8	(-2.6, 1.1)	35.4 ± 4.1	51.5 ± 5.7	-0.8	(-3.0, 1.3)	2.4	(0.1, 4.6)
Q3 (2.40/2.44)	49	26.0 ± 10.5	47	16.7 ± 9.4	2.4	(-1.8, 6.5)	-1.0	(-4.5, 2.5)	13.3 ± 5.8	8.5 ± 5.5	1.4	(-1.0, 3.8)	-0.7	(-2.8, 1.3)	36.7 ± 5.5	51.7 ± 5.6	-1.0	(-3.4, 1.3)	1.8	(-0.4, 4.0)
Q4 (3.25/3.19)	41	24.0 ± 9.7	46	16.2 ± 9.5	0.3	(-4.3, 4.9)	-1.6	(-5.7, 2.6)	11.8 ± 5.4	8.1 ± 5.2	0.1	(-2.4, 2.7)	-1.3	(-3.6, 1.0)	36.7 ± 4.9	50.2 ± 5.2	-1.3	(-3.8, 1.2)	0.0	(-2.3, 2.3)
P, trend		0.33		0.91	0.80		0.49		0.56	0.89	0.83		0.31		>0.99	0.30	0.31		0.80	
P, interaction		0.53			0.51				0.61		0.39				0.61		0.59			

This article is protected by copyright. All rights reserved.

Author Manuscript

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

Footnotes to Table S7

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as a continuous predictor.

[d] From linear regression models with an indicator for male sex as a predictor and cross-product terms between the indicator and all other predictors in the model.

This article is protected by copyright. All rights reserved.

Table S8. Percent total and truncal fat[a] at 16 y by serum n-6 polyunsaturated fatty acid biomarkers at 1 years of age among children from Santiago, Chile, stratified by sex

	% Total fat						% Truncal fat			
	Mean ± SD				Adjusted mean difference (95% CI)[b]		Mean ± SD		Adjusted mean difference (95% CI)	
Fatty acid quartile (median, girls/boys, weight % of total FA)	N	Girls	N	Boys	Girls	Boys	Girls	Boys	Girls	Boys
N-6										
LA (18:2 n-6)										
Q1 (17.19/16.24)	47	37.9 ± 7.5	51	19.5 ± 8.3	Reference	Reference	49.7 ± 5.3	48.3 ± 6.2	Reference	Reference
Q2 (21.28/21.46)	45	35.7 ± 6.5	50	24.6 ± 9.1	-1.4 (-4.5, 1.7)	5.1 (1.4, 8.7)	50.3 ± 5.3	49.1 ± 6.8	1.0 (-1.2, 3.3)	1.5 (-1.0, 4.0)
Q3 (25.95/25.80)	36	36.8 ± 7.7	53	22.6 ± 8.6	-0.9 (-3.9, 2.2)	4.2 (0.4, 7.9)	49.6 ± 4.9	49.4 ± 6.3	0.9 (-1.2, 2.9)	2.0 (-0.6, 4.7)
Q4 (31.19/30.88)	50	36.9 ± 7.0	50	22.6 ± 9.1	-1.4 (-4.7, 2.0)	3.9 (-0.8, 8.5)	48.9 ± 5.3	49.2 ± 6.3	-0.1 (-2.4, 2.1)	2.5 (-0.9, 5.9)
P, trend[c]		0.68		0.19	0.51	0.14	0.35	0.44	0.86	0.14
P, interaction[d]		0.21			0.12		0.23		0.19	
GLA (18:3 n-6)										
Q1 (0.00/0.00)	36	35.2 ± 7.1	50	21.8 ± 8.9	Reference	Reference	49.2 ± 4.8	49.4 ± 6.6	Reference	Reference
Q2 (0.07/0.07)	38	37.5 ± 8.9	51	21.5 ± 8.5	1.4 (-1.9, 4.8)	-0.3 (-3.5, 3.0)	50.5 ± 5.4	49.9 ± 6.0	1.4 (-1.1, 3.8)	0.5 (-1.9, 2.8)
Q3 (0.11/0.11)	49	37.1 ± 6.8	47	21.8 ± 9.9	2.0 (-1.0, 4.9)	-0.5 (-3.9, 3.0)	48.7 ± 5.9	49.2 ± 7.0	-0.6 (-2.9, 1.7)	-0.7 (-3.3, 1.8)
Q4 (0.37/0.43)	55	37.2 ± 6.2	56	24.0 ± 8.4	2.4 (-0.4, 5.3)	4.5 (1.2, 7.8)	50.0 ± 4.6	47.7 ± 5.9	1.5 (-0.6, 3.7)	0.3 (-2.2, 2.8)
P, trend		0.42		0.10	0.17	0.003	0.49	0.06	0.16	0.81
P, interaction		0.46			0.14		0.06		0.48	
DGLA (20:3 n-6)										
Q1 (0.44/0.44)	45	36.6 ± 6.3	44	21.6 ± 10.2	Reference	Reference	50.3 ± 5.2	47.8 ± 6.2	Reference	Reference
Q2 (0.61/0.61)	42	37.2 ± 7.4	56	23.9 ± 8.3	1.1 (-1.7, 3.9)	2.8 (-0.7, 6.4)	50.4 ± 4.8	49.8 ± 6.0	0.6 (-1.5, 2.6)	1.6 (-0.7, 3.9)
Q3 (0.75/0.76)	44	37.1 ± 7.0	50	21.1 ± 7.5	0.3 (-2.4, 3.0)	0.7 (-2.7, 4.2)	50.0 ± 4.4	49.2 ± 6.2	0.2 (-2.0, 2.4)	1.9 (-0.5, 4.3)
Q4 (0.97/0.96)	47	36.4 ± 8.1	54	22.4 ± 9.5	-0.4 (-3.3, 2.6)	1.0 (-2.9, 4.8)	47.9 ± 6.0	48.9 ± 7.0	-2.1 (-4.4, 0.1)	2.0 (-0.6, 4.5)
P, trend		0.83		0.94	0.65	0.98	0.03	0.60	0.04	0.15
P, interaction		0.94			0.77		0.07		0.02	

This article is protected by copyright. All rights reserved.

Author Manuscript

AA (20:4 n-6)										
Q1 (0.94/0.95)	42	37.0 ± 6.6	45	22.2 ± 9.3	Reference	Reference	50.4 ± 4.3	49.4 ± 5.9	Reference	Reference
Q2 (1.31/1.31)	51	35.0 ± 7.0	56	23.0 ± 8.9	-0.6 (-3.8, 2.5)	0.7 (-2.8, 4.3)	50.5 ± 5.1	48.9 ± 6.3	2.1 (-0.1, 4.3)	-1.4 (-3.7, 1.0)
Q3 (1.69/1.63)	46	37.2 ± 7.0	52	19.9 ± 8.8	1.7 (-1.6, 5.0)	-2.9 (-6.6, 0.7)	48.9 ± 5.4	49.1 ± 7.1	0.3 (-2.0, 2.6)	-1.9 (-4.6, 0.8)
Q4 (2.30/2.23)	39	38.7 ± 7.7	51	24.1 ± 8.3	2.6 (-1.2, 6.3)	0.9 (-3.7, 5.4)	48.5 ± 5.8	48.6 ± 6.2	0.9 (-2.2, 3.9)	-2.3 (-5.4, 0.8)
P, trend		0.10		0.45	0.08	0.93	0.04	0.59	0.99	0.17
P, interaction		0.59			0.30		0.31		0.33	
N-6:N-3 ratio										
Q1 (12.6/12.9)	46	37.6 ± 7.6	45	22.3 ± 9.3	Reference	Reference	51.1 ± 5.1	51.6 ± 5.8	Reference	Reference
Q2 (17.9/18.6)	40	36.7 ± 5.6	58	21.7 ± 8.5	1.5 (-1.7, 4.8)	1.4 (-3.4, 6.3)	49.2 ± 5.0	46.9 ± 5.8	-1.3 (-4.0, 1.5)	-0.3 (-3.4, 2.7)
Q3 (22.9/22.8)	46	36.0 ± 7.9	48	23.2 ± 9.4	2.1 (-1.7, 6.0)	2.7 (-2.4, 7.8)	48.2 ± 5.4	50.1 ± 6.2	-2.4 (-5.4, 0.5)	3.4 (-0.2, 7.0)
Q4 (31.7/32.1)	46	37.0 ± 7.4	53	22.3 ± 8.8	3.7 (-0.7, 8.1)	4.7 (-1.2, 10.7)	50.0 ± 5.0	48.0 ± 6.7	-1.1 (-4.7, 2.6)	3.4 (-0.8, 7.7)
P, trend		0.68		0.86	0.10	0.09	0.39	0.08	0.60	0.03
P, interaction		0.69			0.74		0.43		0.05	
Desaturase activity indices										
Δ6-Desaturase index (GLA/LA)										
Q1 (0.000/0.000)	41	34.8 ± 7.3	51	21.9 ± 8.6	Reference	Reference	49.4 ± 4.8	49.6 ± 6.6	Reference	Reference
Q2 (0.003/0.003)	37	37.9 ± 8.6	45	22.4 ± 8.9	1.6 (-1.8, 5.0)	0.6 (-2.9, 4.0)	49.5 ± 5.7	50.0 ± 6.1	0.5 (-2.1, 3.0)	-0.2 (-2.6, 2.2)
Q3 (0.005/0.005)	41	36.8 ± 6.7	55	21.1 ± 9.5	1.6 (-1.3, 4.6)	-0.4 (-3.9, 3.0)	49.0 ± 5.6	48.5 ± 7.0	-0.3 (-2.7, 2.0)	-1.4 (-3.9, 1.1)
Q4 (0.015/0.020)	59	37.6 ± 6.2	53	24.0 ± 8.5	3.1 (0.4, 5.9)	3.3 (0.1, 6.6)	50.3 ± 4.9	48.1 ± 5.7	1.6 (-0.5, 3.7)	-0.1 (-2.4, 2.3)
P, trend		0.16		0.14	0.03	0.03	0.28	0.14	0.09	0.97
P, interaction		0.79			0.71		0.07		0.28	
Δ5-Desaturase index (AA/DGLA)										
Q1 (1.57/1.57)	43	35.9 ± 6.6	59	22.4 ± 9.9	Reference	Reference	49.8 ± 4.7	50.0 ± 6.1	Reference	Reference
Q2 (1.93/1.94)	45	35.7 ± 7.5	52	22.1 ± 8.5	0.2 (-3.1, 3.6)	-1.4 (-4.8, 1.9)	50.0 ± 5.1	48.7 ± 7.1	0.2 (-2.1, 2.4)	-1.8 (-4.1, 0.5)
Q3 (2.40/2.44)	49	38.6 ± 7.3	47	22.5 ± 8.6	2.3 (-0.9, 5.5)	-1.4 (-4.8, 2.1)	50.2 ± 5.1	48.6 ± 6.4	0.9 (-1.3, 3.1)	-2.2 (-4.6, 0.2)
Q4 (3.25/3.19)	41	37.0 ± 7.0	46	22.3 ± 8.5	1.0 (-2.4, 4.3)	-1.4 (-5.3, 2.5)	48.3 ± 5.9	48.4 ± 5.8	-0.3 (-3.0, 2.3)	-3.1 (-5.8, -0.4)
P, trend		0.24		0.99	0.48	0.53	0.20	0.21	0.80	0.04
P, interaction		0.45			0.35		0.99		0.17	

Author Manuscript

This article is protected by copyright. All rights reserved.

Author Manuscript

Footnotes to Table S8

[a] Measured by dual-energy X-ray absorptiometry.

[b] From linear regression models with a given body composition measure as the outcome and indicator variables for PUFA quartiles as predictors. In addition, all models were adjusted for sex, birth weight (large vs. average for gestational age), breastfeeding (<6 mo, ≥6 mo w/ bottle feeding, ≥6 mo exclusive), Graffar index (indicator variables for quintiles), BMI at 1 y (continuous), and total serum trans fatty acids. All n-6 PUFA are adjusted for ALA and total long-chain n-3 PUFA. All long chain PUFA are adjusted for their precursor PUFA. Covariate fatty acids are represented with linear and restricted cubic spline terms.

[c] From linear regression models with a variable representing medians of PUFA quartiles introduced as a continuous predictor.

[d] From linear regression models with an indicator for male sex as a predictor and cross-product terms between the indicator and all other predictors in the model.

This article is protected by copyright. All rights reserved.